CURRICULUM VITAE
Athens, 08-01-2016
Name:
Evangelos Terpos
Specialty:
Associate Professor of Hematology
Date of Birth:
11 February 1967
Nationality:
Greek
Marital Status:
Married with two children
Work Address:
Department of Clinical Therapeutics,
University of Athens School of Medicine,
Alexandra General Hospital,
80 Vas. Sofias Avenue, 11528, Athens, Greece
Tel: +30-213-2162846
Fax: +30-213-2162511
e-mails: eterpos@med.uoa.gr; e.terpos@imperial.ac.uk
Qualifications of professional bodies:
M.D.
University of Thessaloniki, Greece
Specialty of Hematology
University of Athens, Greece
Ph.D.
University of Athens, Greece
GMC Qualification in the UK: Full, No 6031599 (specialist in Hematology)
1990
2000
2002
2001
Membership of Societies:
1. Greek Society for Hematology (Vice President of the Lymphoproliferative Disorders
Study Group 2011-2013; President of the same Group 2013-2015; Member of the
Board of the Greek Society for Hematology 2014-2016)
2. European Myeloma Network (Co-Chair of the Guidelines Committee of the EMN since
2012)
3. International Myeloma Working Group (Co-Chair of the Bone Subgroup of the IMWG
since 2012)
4. International Myeloma Society
5. British Society for Haematology
6. American Society of Hematology
7. European Hematology Association
8. International Society for Bone and Mineral Research
Awards and Prizes:
1. Research Fellowship from the Greek National Academy Institute for the years 19861989.
2. Postgraduate Fellowship from the “Lilian Voudouri” Foundation for 2001 & 2002.
3. “Arkagathos Goutas” Research Award from the Greek Society of Hematology in 1997.
4. Best oral presentation in the Annual Meeting of the Greek Society of Hematology of
2001, 2008, 2009, 2013, 2014 and 2015; best poster presentation in the Annual
Meeting of the Greek Society of Hematology of 2005, 2008 and 2009.
5. Second award for best oral presentation in the Annual Meeting of the Greek Society for
Medical Oncology in 2008 and 3rd award for best oral presentation in 2010.
6. Young Investigator Award of the Greek Society of Haematology in 2010.
7. Young Investigator Award of the International Myeloma Workshop 2011 in Paris.
8. Second award “Sotiris Papastamatis” of the Annual Greek Medical Congress in 2012.
9. Best poster award of the 2nd Aegean Hematology Oncology Symposium in 2015.
Current Appointments:
Associate Professor of Hematology in the Department of Clinical Therapeutics, University
of Athens School of Medicine, Alexandra General Hospital, Athens, Greece (since
08.05.2014)
&
Honorary Senior Lecturer in the Department of Haematology, Faculty of Medicine Imperial
College London, Hammersmith Hospital, London, UK (since 26.09.2003).
Previous Appointments:
Post
Assistant Profesor of
Hematology
Consultant Hematologist
& Director
Consultant Hematologist
Consultant Hematologist
Specialist Registrar
Registrar
General Practitioner
House Officer
Institution
Department of Clinical Therapeutics, National
and Kapodistrian University of Athens, Athens,
Greece
Department of Hematology & Medical
Research, 251 General Air Force Hospital,
Athens, Greece
Department of Hematology, Faculty of
Medicine Imperial College London,
Hammersmith Hospital, London, UK
Department of Hematology, 251 General Air
Force Hospital, Athens, Greece
Department of Hematology, University of
Athens School of Medicine, Laikon General
Hospital, Athens, Greece
Second Department of Medicine, 251 General
Air Force Hospital, Athens, Greece
Department of Medicine, 120 Wing of Air
Force Training, Kalamata, Greece
Second Department of Medicine, 251 General
Air Force Hospital, Athens, Greece
Dates
7.10.09-07.05.14
6.10.03-30.09.09
1.10.01-30.09.03
12.01.0030.09.01
21.11.9521.11.99
24.10.9325.10.95
12.10.9120.10.93
21.09.90-1.10.91
Clinical Experience:
In the Department of Clinical Therapeutics of the University of Athens, in Alexandra
Hospital (Athens, Greece) I work as an Associate Professor of Therapeutics-Hematology.
This post is both clinical and academic. In the clinical setting, I am involved mainly in the
management of patients with plasma cell dyscrasias, especially of patients with multiple
myeloma, but also with systemic amyloidosis and Waldenstrom’s macroglobulinemia. I am
also involved in the management of patients with other hematological malignancies
including lymphomas and myelodysplastic syndromes. I have Ward duties, “on-call” duties,
and I participate in the Ward Rounds of the Department.
In my previous appointments as a Consultant, I always worked in the field of hematological
malignancies. In the Air Force Hospital of Athens, I was the leading physician for patients
with multiple myeloma and myelodysplastic syndromes, while I had Ward duties for patients
who had been given high dose chemotherapy with autologous stem cell support.
In the Hammersmith Hospital of Imperial College London, I had a myeloma clinic, twice a
week, along with Ward responsibilities in the transplant patients (both autologous and
allogeneic transplantation). I had also “on-call” duties and I participated in the Ward
Rounds of the Department.
2
Research Experience:
In my PhD thesis (University of Athens: 1997-2001) I evaluated the role of red cells with
paroxysmal nocturnal hemoglobinuria phenotype in aplastic anemia, myelodysplastic
syndromes (MDS) and other hematological malignancies, including acute leukemias and
multiple myeloma. The main finding is that increased incidence of PNH phenotype is
present in MDS patients and that these patients have better outcome when ther are treated
with immunosuppressive agents.
In Imperial College (2001-2003), my main research interest was the biology and
management of myeloma-related bone disease and the effect of novel anti-myeloma
agents (proteasome inhibitors and immunomodulatory drugs) on bone metabolism of
myeloma patients. I have extensively studied the role of RANKL/osteoprotegerin pathway,
CCL-3, and dickkopf-1 in the biology of bone destruction in myeloma.
When I returned to Athens I was appointed as the Director of the Department of Medical
Research in the Air Force Hospital (2003-2009). During that period, the department was
fully equipped with the recent technology and was considered as a reference center for the
evaluation of bone metabolism in different disorders. As a Director of that Department and
after that, as an Assistant initialy and now Associate Professor in the University of Athens I
continue to study bone metabolism of myeloma patients. Especially, I have assessed the
role of Wnt signaling (dickkopf-1 and sclerostin), activin-A, and recently of periostin and
semaphorin-4D in the pathogenesis of myeloma osteolytic disease. I have also evaluated
the value of markers of bone remodeling in reflecting the extent of osteolytic disease in
myeloma along with their prognostic value in predicting the time of myeloma progression to
bone and in predicting the overall survival of the patients. I have also studied and continue
to study the effect of novel anti-myeloma agents (proteasome inhibitors and
immunomodulatory drugs) on bone metabolism of myeloma patients and the role of novel
bone-targeted therapies (i.e. sotatercept and denosumab) in the management of myeloma
patients with bone disease. Finally, I study the role of modern imaging techniques (mainly
MRI but also PET/CT) in the more accurate definition of bone disease as a criterion for
symptomatic myeloma and also the role of modern imaging in the definition of complete
response after anti-myeloma therapy.
Other research interests in the field of multiple myeloma include the value of biochemical
marker of renal injury in evaluating renal impairment, the study of angiogenic cytokines in
the biology of the disease and the study of adhesion molecules in the pathogenesis of
myeloma. Furthermore, in collaboration with members of the faculty of Imperial College
London I work in the following projects: i) gene expression profiling in multiple myeloma; ii)
invariant NKT cells and glycosphingolipids in the pathogenesis of multiple myeloma; iii)
clinical drug resistance, interconvertible phenotypic and functional states of tumorpropagating cells in multiple myeloma; and iv) long term effect of imatinib and dasatinib on
bone metabolism of newly diagnosed patients with chronic myeloid leukemia.
I have also studied bone metabolism in other hematological disorders including betathalassemia and hemophilia, as well as in other malignant diseases including bone
metastases of different etiology, Gaucher Disease, Chronic Myeloid Leukemia,
Langerhan’s Histiocytosis and Paget’s disease of the bone.
My clinical research interests include the role of novel anti-myeloma agents in the treatment
of myeloma patients. I have participated and continue to participate as a principal
investigator or as a sub-investigator in several international and national clinical trials with
novel agents for myeloma patients.
My research activity has led to the publication of several papers in high impact factor
journals, including Journal of Clinical Oncology, Blood, Leukemia, Haematologica, British
Journal of Haematology, Annals of Oncology and others.
3
Teaching experience:
All my posts have involved teaching commitments. The more junior posts involved teaching
medical students while the more senior posts involved teaching senior house officers and
registrars in the in-patient and out-patient setting.
As an Associate Professor in the University of Athens I teach the medical students in the
fields of “Therapeutics”, “Internal Medicine”, “Hematology” and “Medical Oncology”. I am
also supervising graduate students and post-doc doctors.
I also give several lectures participating in the BSc Modules of the Faculty of Medicine of
Imperial College London in the fields of “Multiple Myeloma”, “Myelodysplastic Syndromes”
and “Thalassemia-Associated Bone Loss”.
I have given more than 60 lectures in educational programs of University
Departments or post-graduate courses (below I describe the 10 more important to my
opinion):
1. “Treatment of Low-risk Myelodysplasia”; Annual Educational Program of the
Department of Hematology, Faculty of Medicine Imperial College London, U.K.
(05.29.2002).
2. “Autologous Transplantation and Bone Disease in Myeloma”; Annual Educational
Program of the Department of Hematology, Faculty of Medicine Imperial College
London, U.K. (05.14.2003).
3. “The Proteasome Inhibitor Bortezomib in Multiple Myeloma”; 35th Post-Graduate
Course “Advances in Haematology” that was held by the Department of Hematology,
Imperial College London (06.19.2003).
4. “Proteasome Inhibitors and Haematological Malignancies”; Annual Educational
Program of the Kennedy Institute of Rheumatology, University of Oxford, U.K.
(10.27.2004).
5. “Pathogenesis and new therapies in osteoporosis in thalassaemia” and “Molecular
mechanisms of osteoclasts and osteoblasts in normal and abnormal bone disorders”;
Master of Science (MSc) in Haemoglobinopathies, University College of London,
U.K. (01.11.2008).
6. “Anemia Management in Low Risk Myelodysplastic Syndromes”; Annual Educational
Program of the Department of Hematology of McGill University, Montreal, Canada
(05.01.2008).
7. “Novel aspects on Multiple Myeloma Bone Disease”; Annual Educational Program of
the Department of Hematology in Princess Margaret Hospital, University of Toronto,
Canada (09.19.2008).
8. “Myeloma Bone Disease and Proteasome Inhibition Therapies”; Annual Educational
Program of the Department of Hematology of the Jagiellonian University, Cracow,
Poland (10.16.2010).
9. “Biology and Management of Myeloma Bone Disease”; Annual Educational Program
of the Department of Hematology of Royal Adelaide Hospital, Adelaide, Australia
(05.22.2012).
10. “Current treatment and future direction in the management of multiple myeloma”;
Annual Educational Program of the Department of Hematology of Gunma University,
Gunma, Japan (04.09.2013).
4
I have given more than 130 lectures in International and National Conferences (below I
describe the 10 more important to my opinion):
1. “RANK and MIP-1α in Multiple Myeloma: Clinical Implications”; 10th International
Myeloma Workshop, Sidney, Australia (04.13.2005).
2. Meet-the-Expert: “Disease Complications in Multiple Myeloma”; 10th Congress of the
European Hematology Association, Stockholm, Sweden (06.05.2005).
3. “Osteonecrosis of the Jaw in patients with Multiple Myeloma who receive bisphosphonates therapy”; 6th Ιnternational Meeting on Cancer Induced Bone Disease, San Antonio,
TX, U.S.A. (12.14.2006).
4. “The role of biochemical markers of bone metabolism in Multiple Myeloma; adverse
events of bisphosphonates administration”; 11th International Myeloma Workshop, Kos,
Greece (06.26.2007).
5. “Τhe role of bone markers in thalassemia: a haematologic perspective”; 11th International
Conference on Thalassemia and Haemoglobinopathies, Singapore (10.08.2008).
6. “The effect of novel anti-myeloma agents on bone metabolism”; 12th International
Myeloma Workshop, Washington, DC, USA (02.27.2009).
7. “Management of Multiple Myeloma-related bone disease”; 52nd Annual Meeting of the
American Society of Hematology, Orlando, FL, USA (12.03.2010).
8. “Should we use markers of bone remodelling in myeloma? Which one and when?”; 13th
International Myeloma Workshop, Paris, France (05.04.2011).
9. “The role of imaging and bone markers in the evaluation of bone disease in multiple
myeloma” & “Markers of Renal Injury”; 14th International Myeloma Workshop, Kyoto,
Japan (04.04.2013 & 04.06.2013).
10. “Bone Support in Relapsed/Refractory Multiple Myeloma”; 15th International Myeloma
Workshop, Rome, Italy (24.09.2015).
Important invited talks to follow:
1. “Myeloma Bone Disease: Can we do better?” Educational program of the European
Calcified Tissue Society Annual Meeting, Rome, Italy (14.05.2016).
2. “The evolving role of imaging in myeloma diagnosis and care” Educational program of the
American Society for Clinical Oncology Annual Meeting, Chicago, USA (04.06.2016).
3. “Pathophysiology and diagnosis of multiple myeloma bone disease” Educational program
of the 21st Congress of the European Society of Hematology, Copenhagen, Denmark (912.06.2016).
Other professional activities:
Participation in Conferences:
 Member of the Organizing Committee in 2 International (11th International Myeloma
Workshop, Kos, Greece, 2007; 2nd Aegean hematology Oncology Symposium, Chios,
Grece, 2015) and in 5 Greek Conferences.
 Member of the Scientific Committee in 3 International (29th ESMO Meeting, Madrid,
Spain, 2014; 30th ESMO Meeting, Copenhagen, Denmark, 2015; 2nd Aegean
Hematology Oncology Symposium, Chios, Greece, 2015) and in 6 National
Conferences.
 Chairman in scientific events in 18 International and 10 National Conferences.
 Reviewer of abstracts in 12 International (ASH 2006, 2008 & 2012; EHA 2005, 2007,
2008 & 2013; EBMT 2011, 2013, 2014, 2015 & 2016) and 8 Greek National
Conferences.
5




Reviewer of papers of the Educational books of 3 International Conferences (ASH
2009, ICDDT 2010 & EHA 2014).
Editor-in-Chief of the Educational book of the 2011 and 2015 Greek Society of
Hematology Annual Meetings.
Author of 425 abstracts that were presented in International Conferences (first author in
145 (34%) abstracts and last author in 85 (20%).
Author of 202 abstracts that were presented in Greek Conferences (first author in 76
(38%) abstracts and last author in 41 (20%).
Member of the Editorial Board of Scientific Journals
 Editor-in-Chief of Hematology & Leukemia
 Member of the Editorial Board of Haematologica
 Member of the Editorial Board of Haema
 Member of the Editorial Board of Archives of Greek Medicine
 Member of the Editorial Board of Hematology Reviews
 Member of the Editorial Board of Clinical & Experimental Medicine
Ad hoc reviewer of more than 70 journals including
 British Journal of Haematology
 Haematologica
 Leukemia
 Blood
 Clinical Cancer Research
 Cancer Research
 Bone
 Oncologist
 Nature Reviews: Clinical Oncology
 Lancet Oncology
 Lancet
 Journal of Clinical Oncology
 Journal of Clinical Endocrinology and Metabolism
2013
2008-2014
2002-2010
since 2007
since 2009
since 2012
since 2002
since 2003
since 2004
since 2007
since 2007
since 2008
since 2008
since 2008
since 2009
since 2010
since 2010
since 2012
since 2013
Member of Grants Panel Committees
 EHA (European Hematology Association) Fellowships and Grants Panel Committee
(2006-2010).
 Grants Evaluating Committee of the Health Research Board of Ireland (2006).
 Grants Reviewer for the Swiss National Science Foundation (2007).
 Grants Reviewer for the Multiple Myeloma Research Foundation (2007, 2008, 2011 &
2015).
 Grants Reviewer for Medical Research Council of the U.K. (2008 & 2011).
 Grants Reviewer for the Institute for Cancer Research of the U.K. (2007-2009).
 Grants Reviewer for the Leukemia & Lymphoma Research Foundation of the U.K.
(2009, 2014 & 2015).
 Grants Reviewer for “Associazione Italiana per la Ricerca sul Cancro” (2011 & 2014).
 Grants Reviewer for the European Calcified Tissue Society (2011).
 Grants Reviewer for the International Myeloma Foundation (2012-2015).
 Grants Reviewer for the Czech Health Research Council (2015).
6
PUBLICATIONS
I. Chapters in Books:
1. Terpos E, Rahemtulla A. Myeloma. In: Hoffbrand V, Catovsky D, Tuddenham EGD,
(eds), Postgraduate Haematology, Fifth Edition, Blackwell Publishing, London, 2005, pp.
681-702.
2. Terpos E, Syrigos KN. Pathophysiology and management of bone metastases in lung
cancer. In: Syrigos KN, Nutting CM, Roussos C (eds), Tumors of the Chest: Biology,
Diagnosis and Management, Springer, Berlin/Heidelberg/New York, 2006, pp. 551-562.
3. Terpos E, Rahemtulla A. Hodgkin’s Lymphoma. In: Young C (ed), BMJ Clinical
Evidence, BMJ Publising Group Ltd, London, 2006, pp. 1-21.
4. Meletis J, Terpos E. The role of stem cell transplantation in the treatment of
myelodysplastic syndromes. In: Parsons DW (ed), Stem Cells and Cancer, Nova
Science Publishers, New York, 2007, pp. 161-182.
5. Terpos E, Meletis J. Autologous and allogeneic stem cell transplantation for multiple
myeloma. In: Parsons DW (ed), Stem Cells and Cancer, Nova Science Publishers, New
York, 2007, pp. 183-207.
6. Terpos E, Meletis J. Biochemical markers of bone remodelling for multiple myeloma. In:
Chang DH (ed), Tumor Markers Research Focus, Nova Science Publishers, New York,
2007, pp. 3-31.
7. Terpos E, Rahemtulla A. Hodgkin’s Lymphoma. In: Young C (ed) BMJ Clinical
Evidence, BMJ Publising Group Ltd, London, 2009, pp. 1-30.
8. Terpos E. Biochemical markers of bone remodeling in multiple myeloma. In: Roodman
G (ed), Myeloma Bone Disease, Springer New York Dordrecht Heidelberg London,
2010; 63-90.
9. Cavenagh J, Raje N, Terpos E, Croucher PI. Bone Disease. In: Richardson PG &
Anderson KC (eds), Multiple Myeloma, Second Edition, Remedica Publishing London
Chicago, 2011, pp. 157-190.
10. Terpos E, Gkotzamanidou M, Christoulas D, Dimopoulos MA. Osteoimmunology and
Cancer: clinical implications. In: Mavragani CP (ed), Autoimmune Disorders:
Pathogenetic Aspects, InTech, Rijeka, Croatia, 2011, pp. 489-508.
11. Polyzos SA, Anastasilakis AD, Makras P, Terpos E. Vitamin D levels and
bisphosphonate treatment in patients with Paget’s disease of bone. In: Lerner V and
Miodownik C (eds), Vitamin D Deficiency, Nova Science Publishers, New York, 2012,
pp. 169-175.
12. Dimopoulos MA, Terpos E. New insights in Waldenström’s Macroglobulinemia. In:
Anagnostou D and Matutes E (eds), Bone Marrow Lympoid Infiltrates: Diagnosis and
Clinical Impact, Springer New York Dordrecht Heidelberg London, 2013, pp. 223-236.
13. Terpos E. The effect of novel anti-myeloma agents on bone metabolism. In: Munshi NC
and Anderson KC (eds), Advances in Biology and Therapy of Multiple Myeloma, Volume
2: Translational and Clinical research, Springer New York Heidelberg Dordrecht London,
2013, pp. 257-275.
7
14. Terpos E, Christoulas D. Involvement of osteocytes in cancer bone niche. In: Heymann
D (ed), Bone Cancer: Primary Bone Cancers and Bone Metastases), 2nd edition,
Academic Press, Elsevier, San Diego CA, Waltham MA, 2015, pp. 65-72.
15. Terpos E, Kanellias N, Giannopoulos K. Biologia choroby kostnej w przebiegu
szpiczaka plazmocytowego. In: Dmoszynskiej A, Giannopoulos K (eds), Szpiczak
plazmocytowy I inne dyskrazje plazmocytowe, Wydawnictwo Czelej Sp. Z o.o., 2015, pp.
149-158 (in Polish).
16. Terpos E. Bone Disease. In: Mohty M and Harousseau J-L (eds), Handbook of Multiple
Myeloma, Springer International Publishing Switzerland, 2015, pp.79-90.
II. Papers in Educational Programs & Proceedings of Meetings:
1. Dimopoulos MA, Anagnostopoulos A, Terpos E. Novel drugs in the treatment of
multiple myeloma. Hematology (EHA Educational Program) 2005; 1: 211-215.
2.
Terpos E. Pathogenesis of bone disease in multiple myeloma: clinical implications.
Proccedings of the 9th International Conference “Drug and Gene-based Therapies”, pp
85-87 (Agia Pelagia, Crete, 2-8/9/2006).
3. Terpos E. Bone Disease: Pathophysiology & Management. Proceedings of the ESH
International Conference on Multiple Myeloma and other Monoclonal Gammopathies:
pp. 1-3 (Cascais, Portugal, 6-9 March 2008).
4. Terpos E. Multiple myeloma: options for relapsed/refractory disease. Educational Book
of the 3rd Balkan Haematological Day, pp 14-20 (Sinaia, Romania, 3/10/2008).
5. Terpos E, Christoulas D, Kastritis E, Migkou M, Gavriatopoulou M, Dimopoulos MA.
Novel anti-myeloma agents and bone metabolism: implications into the management of
myeloma bone disease. Educational Book of the XII International Myeloma Workshop,
pp 1-3 (Washington, DC, USA, 26/2-1/3/2009).
6. Dimopoulos MA, Kastritis E, Terpos E. Multiple myeloma frontline treatment in the
elderly: the role of bortezomib. Haematology 2010: 48-54 (5th Balkan Day of
Haematology, Thessaloniki, Greece, 11/11/2010).
7. Dimopoulos MA, Terpos E. Multiple Myeloma. Annals of Oncology 2010;21 Suppl
7:vii143-vii150.
8. Dimopoulos MA, Terpos E. Renal Insufficiency & Failure. Hematology (ASH
Educational Program) 2010, 431-436.
9. Richardson P, Anderson K, Bensinger W, San Miguel JF, Terpos E. Recent Advances
in the treatment of multiple myeloma: Proceedings from a post-ASH roundtable. Faculty
Perspectives 2011; 3(4): 4-20.
10. Richardson P, Anderson K, Giralt SA, San Miguel JF, Terpos E. Recent Advances in
the treatment of multiple myeloma: Proceedings from a post-IMW roundtable. Faculty
Perspectives 2011; 3(5): 3-16.
11. Dimopoulos MA, Terpos E. Advances in the treatment of multiple myeloma. European
Journal of Cancer 2011; 47 Suppl 3: S306-S308.
8
III. Reviews/Editorials/Consensus papers/Meta-analyses/Guidelines in Peer-reviewed
Journals:
1. Meletis J, Terpos E. Recent insights into the pathophysiology of paroxysmal nocturnal
hemoglobinuria. Medical Science Monitor 2003;9:161-72.
2. Terpos E, Politou M, Rahemtulla A. New insights into the pathophysiology and
management of bone disease in multiple myeloma. British Journal of Haematology
2003;123:758-69.
3. Terpos E, Rahemtulla A. Bisphosphonate treatment for multiple myeloma. Drugs of
Today 2004;40:29-40.
4. Voskaridou E, Terpos E. New insights into the pathophysiology and management of
osteoporosis in patients with beta thalassaemia. British Journal of Haematology
2004;127:127-39.
5. Terpos E, Politou M, Rahemtulla A. The role of markers of bone remodelling in multiple
myeloma. Blood Reviews 2005;19:125-42.
6. Terpos E, Rahemtulla A, Dimopoulos MA. Current treatment options for myeloma.
Expert Opinion on Pharmacotherapy 2005;6:1127-42.
7. Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management.
Annals of Oncology 2005;16:1223-31.
8. Terpos E, Rahemtulla A. New insights into the treatment of multiple myeloma.
Postgraduate Doctor Journal 2005;21:123-8.
9. Terpos E, Politou M, Viniou N, Rahemtulla A. Significance of macrophage inflammatory
protein 1-alpha (MIPLeukemia & Lymphoma 2005;46:1699707.
10. Terpos E, Eleutherakis-Papaiakovou V, Dimopoulos MA. Clinical implications of
chromosomal abnormalities in multiple myeloma. Leukemia & Lymphoma 2006;47:80314.
11. Terpos E. Biochemical markers of bone metabolism in multiple myeloma. Cancer
Treatment Reviews 2006;32 (Suppl 1):15-9.
12. Terpos E, Eleutherakis-Papaiakovou V, Dimopoulos MA. Clinical implications of
chromosomal abnormalities in multiple myeloma. Leukemia & Lymphoma 2006;47:80314.
13. Meletis J, Viniou N, Terpos E. Novel agents for the management of myelodysplastic
syndromes. Medical Science Monitor 2006;12:RA194-206.
14. Terpos E. Antibodies to dickkopf-1 protein. Expert Opinion on Therapeutic Patents
2006;16:1453-8.
15. Terpos E. What's new in bone research--anabolics, tissue repair, therapeutic strategies
and more. IDrugs 2006;9:837-40.
9
16. Lipton A, Cook RJ, Coleman RE, Smith MR, Major P, Terpos E, Berenson JR. Clinical
utility of biochemical markers of bone metabolism for improving the management of
patients with advanced multiple myeloma. Clinical Lymphoma & Myeloma 2007;7:346-53.
17. Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and
proteasome inhibition therapies. Blood 2007;110:1098-104.
18. Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone
metabolism of patients with multiple myeloma. Leukemia 2007;21:1875-84.
19. Terpos E, Roussou M, Dimopoulos MA. Bortezomib in multiple myeloma. Expert Opinion
on Drug Metabolism & Toxicology 2008; 4: 639-654.
20. Anargyrou K, Dimopoulos MA, Sezer O, Terpos E. Novel anti-myeloma agents and
angiogenesis. Leukemia & Lymphoma 2008;49:677-89.
21. Terpos E. Have myeloma cells osteoclast-like activity? Implications into the
pathogenesis of myeloma bone disease. Leukemia Research 2008;32:521-2.
22. Mountzios G, Terpos E, Dimopoulos MA. Aurora kinases as targets for cancer therapy.
Cancer Treatment Reviews 2008; 34: 175-82.
23. Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, Terpos E, Sezer
O. The potential of proteasome inhibitors in cancer therapy. Expert Opinion on
Investigational Drugs 2008;17:879-95.
24. Katodritou E, Zervas K, Terpos E, Brugnara C. Use of erythropoiesis stimulating agents
and intravenous iron for cancer and treatment-related anaemia: the need for predictors
and indicators of effectiveness has not abated. British Journal of Haematology
2008;142:3-10.
25. Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, Major P. Bone markers
and their prognostic value in metastatic bone disease: clinical evidence and future
directions. Cancer Treatment Reviews 2008;34:629-39.
26. Terpos E. Bortezomib directly inhibits osteoclast function in multiple myeloma:
implications into the management of myeloma bone disease. Leukemia Research
2008;32:1646-7.
27. Terpos E, Dimopoulos MA. Genetic predisposition for the development of ONJ. Blood
2008;112:2596-7.
28. Terpos E, Christoulas D, Dimopoulos MA. Antibodies to receptor activator of nuclear
factor-kB ligand (RANKL). Expert Opinion on Therapeutic Patents 2008;18:1265-9.
29. Voskaridou E, Terpos E. Pathogenesis and management of osteoporosis in thalassemia.
Pediatric Endocrinology Reviews 2008;6 Suppl 1:86-93.
30. Terpos E, Voskaridou E. Interactions between osteoclasts, osteoblasts and immune
cells: implications into pathogenesis of bone loss in thalassemia. Pediatric Endocrinology
Reviews 2008;6 Suppl 1:94-106.
31. Migkou M, Dimopoulos MA, Gavriatopoulou M, Terpos E. Applications of monoclonal
antibodies for the treatment of hematological malignancies. Expert Opinion on Biological
Therapies 2009;9:207-20.
10
32. Terpos E, Tasidou A, Kastritis E, Eleftherakis-Papaiakovou E, Gavriatopoulou M, Migkou
M, Dimopoulos MA. Angiogenesis in Waldenstrom's Macroglobulinemia. Clinical
Lymphoma & Myeloma 2009;9:46-9.
33. Dimopoulos MA, Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, Migkou M,
Gavriatopoulou M, Tassidou A, Terpos E. Rituximab-based treatments in Waldenström's
Macroglobulinemia. Clinical Lymphoma & Myeloma 2009;9:59-61.
34. Terpos E, Efstathiou E, Christoulas D, Roussou M, Katodritou E, Dimopoulos MA.
RANKL inhibition: Clinical implications for the management of patients with multiple
myeloma and solid tumors with bone metastases. Expert Opinion on Biological Therapies
2009;9:465-79.
35. Terpos E, Cibeira MT, Blade J, Ludwig H. Management of complications in multiple
myeloma. Seminars in Hematology 2009;46:176-89.
36. Gavriatopoulou M, Dimopoulos MA, Christoulas D, Migkou M, Iakovaki M,
Gkotzamanidou M, Terpos E. Dickkopf-1: a suitable target for the management of
myeloma bone disease. Expert Opinion on Therapeutic Targets 2009;13:839-48.
37. Anastasilakis AD, Toulis KA, Polyzos SA, Terpos E. RANKL inhibition for the
management of patients with benign metabolic bone disorders. Expert Opinion on
Investigational Drugs 2009;18:1085-102.
38. Terpos E, Sezer O, Croucher PI, García-Sanz R, Boccadoro M, San Miguel J, Ashcroft J,
Bladé J, Cavo M, Delforge M, Dimopoulos MA, Facon T, Macro M, Waage A, Sonneveld
P. The use of bisphosphonates in multiple myeloma: recommendations of an expert
panel on behalf of the European Myeloma Network. Annals of Oncology 2009;20:130317.
39. Dimopoulos MA, Moulopoulos LA, Terpos E. A new pet for myeloma. Blood
2009;114:2007-8.
40. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst
H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA, Durie BG. International
myeloma working group consensus statement and guidelines regarding the current role
of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia
2009;23:1546-56.
41. Christoulas D, Terpos E, Dimopoulos MA. Pathogenesis and management of myeloma
bone disease. Expert Reviews of Hematology 2009;2:385-98.
42. Anastasilakis AD, Toulis KA, Goulis DG, Polyzos SA, Delaroudis S, Giomisi A, Terpos E.
Efficacy and safety of denosumab in postmenopausal women with osteopenia or
osteoporosis: a systematic review and a meta-analysis. Hormone & Metabolic Research
2009;41:721-9.
43. Polyzos SA, Anastasilakis AD, Terpos E. Paget’s disease of bone: emphasis on
treatment with zoledronic acid. Expert Reviews of Endocrinoly and Metabolism
2009;4:423-34.
44. Katodritou E, Dimopoulos MA, Zervas K, Terpos E. Update on the use of erythropoiesisstimulating agents (ESAs) for the management of anemia of multiple myeloma and
lymphoma. Cancer Treatment Reviews 2009;35:738-43.
11
45. Dimopoulos MA, Terpos E. First-line bortezomib benefits patients with multiple myeloma.
Nature Reviews Clinical Oncology 2009;6:683-5.
46. Meletis J, Terpos E. Transplantation strategies for the management of patients with
myelodysplastic syndromes. Journal of BUON 2009;14:551-64.
47. Anargyrou K, Vassilakopoulos TP, Angelopoulou MK, Terpos E. Incorporating novel
agents in the treatment of myelodysplastic syndromes. Leukemia Research 2010;34:617.
48. Terpos E. Bortezomib down-regulates the osterix expression by osteoblasts in the
myeloma microenvironment: Implications into osteoblast function in myeloma bone
disease. Leukemia Research 2010;34:700-701.
49. Bamias A, Terpos E, Dimopoulos MA. Avascular osteonecrosis of the jaw as a side
effect of bisphosphonate treatment. Onkologie 2010;33:288-289.
50. Terpos E, Voskaridou E. Treatment options for thalassemia patients with osteoporosis.
Annals of the New York Academy of Sciences 2010;1202:237-243.
51. Terpos E, Dimopoulos MA. Intravenous pamidronate for the management of myeloma
bone disease: can the dose be lowered? Lancet Oncology 2010;11:913-914.
52. Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P,
Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT,
Harousseau JL, Anderson KC, Durie BGM on behalf of the International Myeloma
Working Group. The use of biochemical markers of bone remodelling in multiple
myeloma: a report of the International Myeloma Working Group. Leukemia
2010;24:1700-1712.
53. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky
R, Giralt S, Fermand JP, Bladé J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL,
Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Rajkumar SV, Durie
BGM, San Miguel J, on behalf of the International Myeloma Working Group. Renal
impairment in patients with multiple myeloma: a consensus statement on behalf of the
International Myeloma Working Group (IMWG). Journal of Clinical Oncology
2010;28:4976-4984.
54. Zini G, Bain B, Bettelheim P, Cortez J, d'Onofrio G, Faber E, Haferlach T, Kacirkova P,
Lewandowski K, Matutes E, Maynadié M, Meletis J, Petersen BL, Porwit A, Terpos E,
Tichelli A, Vallespí T, Woessner S, Bennett J, Bene MC. A European consensus report
on blood cell identification: terminology utilized and morphological diagnosis concordance
among 28 experts from 17 countries within the European LeukemiaNet network WP10,
on behalf of the ELN Morphology Faculty. British Journal of Haematology 2010;151:359364.
55. Engelhardt M, Udi J, Kleber M, Spencer A, Rocci A, Knop S, Bruno B, Bringhen S, PérezSimón JA, Zweegman S, Driessen C, Patriarca F, Gramatzki M, Terpos E, Sezer O,
Kropff M, Straka C, Johnsen HE, Waage A, Boegsted M, Lokhorst H, Hájek R, Morgan
G, Boccadoro M, Ludwig H, Cavo M, Polliack A, Sonneveld P, Einsele H, Palumbo A.
European Myeloma Network: the 3rd Trialist Forum consensus statement from the
european experts meeting on multiple myeloma. Leukemia & Lymphoma 2010;51:20062011.
12
56. Dimopoulos MA, Terpos E. Lenalidomide: an update on evidence from clinical trials.
Blood Reviews 2010;24S1:S21-S26.
57. Terpos E. Zoledronic acid: a framework of emerging anticancer evidence throughout the
cancer continuum. Critical Reviews in Oncology Hematology 2011;77 Suppl 1:S1-2.
58. Terpos E, Dimopoulos MA, Berenson J. Established role of bisphosphonate therapy for
prevention of skeletal complications from myeloma bone disease. Critical Reviews in
Oncology Hematology 2011; 77 Suppl 1:S13-23.
59. Terpos E, Dimopoulos MA. Interaction between the skeletal and the immune systems in
cancer: mechanisms and clinical implications. Cancer Immunology & Immunotherapy
2011;60:305-317.
60. Terpos E. The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin
on multiple myeloma cells; rationale for the use of combination regimens in myeloma
patients. Leukemia Research 2011;35:295-296.
61. Kastritis E, Terpos E, Dimopoulos MA. Emerging drugs for
Macroglobulinemia. Expert Opinion on Emerging Drugs 2011;16:45-57.
Waldenstrom’s
62. Terpos E, Moulopoulos LA, Dimopoulos MA. Advances in imaging and the management
of myeloma bone disease. Journal of Clinical Oncology 2011;29:1907-15.
63. Terpos E, Dimopoulos MA. Zoledronic acid for all patients with newly diagnosed multiple
myeloma? Lancet Oncology 2011;12:711-2.
64. Polyzos SA, Anastasilakis AD, Makras P, Terpos E. Paget's disease of bone and
calcium homeostasis: focus on bisphosphonate treatment. Experimental and Clinical
Endocrinology & Diabetes 2011;119:519-24.
65. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV, Rosiñol L,
Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C,
Gimsing P, Gramatzki M, Hàjek R, Johnsen HE, Leal Da Costa F, Sezer O, Spencer A,
Beksac M, Morgan G, Einsele H, San Miguel JF, Sonneveld P. Personalized therapy in
multiple myeloma according to patient age and vulnerability: a report of the European
Myeloma Network (EMN). Blood 2011;118:4519-29.
66. Mountzios G, Ramfidis V, Terpos E, Syrigos KN. Prognostic Significance of Bone
Markers in Patients With Lung Cancer Metastatic to the Skeleton: A Review of Published
Data. Clinical Lung Cancer 2011;12:341-9.
67. Coleman R, Costa L, Saad F, Cook R, Hadji P, Terpos E, Garnero P, Brown J, Body JJ,
Smith M, Lee KA, Major P, Dimopoulos M, Lipton A. Consensus on the utility of bone
markers in the malignant bone disease setting. Critical Reviews in Oncology Hematology
2011;80:411-32.
68. Terpos E. Bisphosphonate anticancer activity in multiple myeloma. Anticancer Agents in
Medicinal Chemistry 2012;12:123-8.
69. Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi
N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo
M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R,
Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M,
Lonial S, Jagannath S, Bladé J, Miguel JS, Morgan G, Anderson KC, Durie BG,
13
Sonneveld P. Management of treatment-emergent peripheral neuropathy in multiple
myeloma. Leukemia 2012;26:595-608.
70. Kleber M, Udi J, Metzke B, Terpos E, Roodman GD, Morgan G, Dispenzieri A, Einsele
H, Wäsch R, Engelhardt M. Challenging the current approaches to multiple myelomaand other cancer-related bone diseases: from bisphosphonates to targeted therapy.
Leukemia & Lymphoma 2012;53:1057-61.
71. Voskaridou E, Christoulas D, Terpos E. Sickle-cell disease and the heart: review of the
current literature. British Journal of Haematology 2012;157:664-73.
72. Gkotzamanidou M, Dimopoulos MA, Kastritis E, Christoulas D, Moulopoulos LA, Terpos
E. Sclerostin: a possible target for the management of cancer-induced bone disease.
Expert Opinion on Therapeutic Targets 2012;16:761-9.
73. Zangari M, Terpos E, Zhan F, Tricot G. Impact of bortezomib on bone health in
myeloma: A review of current evidence. Cancer Treatment Reviews 2012;38:968-80.
74. Dimopoulos MA, Terpos E, Goldschmidt H, Alegre A, Mark T, Niesvizky R. Treatment
with lenalidomide and dexamethasone in patients with multiple myeloma and renal
impairment. Cancer Treatment Reviews 2012;38:1012-9.
75. Terpos E, Kastritis E, Dimopoulos MA. Prevention and treatment of myeloma bone
disease. Current Hematologic Malignancy Reports 2012;7:249-57.
76. Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, Garcia-Sanz R, Ocio
EM, Morra E, Morel P, Anderson KC, Patterson CJ, Munshi NC, Tedeschi A, Joshua DE,
Kastritis E, Terpos E, Ghobrial IM, Leleu X, Gertz MA, Ansell SM, Morice WG, Kimby E,
Treon SP. Response assessment in Waldenström macroglobulinaemia: update from the
VIth International Workshop. British Journal of Haematology 2013;160:171-6.
77. Fields SZ, Parshad S, Anne M, Raftopoulos H, Alexander MJ, Sherman ML, Laadem A,
Sung V, Terpos E. Activin receptor antagonists for cancer-related anemia and bone
disease. Expert Opinion on Investigational Drugs 2013;22:87-101.
78. Terpos E, Roodman GD, Dimopoulos MA. Optimal use of bisphosphonates in patients
with multiple myeloma. Blood 2013;121:3325-8.
79. Dimopoulos MA, Terpos E, Kastritis E. Proteasome inhibitor therapy for Waldenström's
Macroglobulinemia. Clinical Lymphoma, Myeloma & Leukemia 2013;13:235-7.
80. Psaltopoulou T, Sergentanis TN, Kanellias N, Kanavidis P, Terpos E, Dimopoulos MA.
Tobacco smoking and risk of multiple myeloma: A meta-analysis of 40 observational
studies. International Journal of Cancer 2013;132:2413-31.
81. Terpos E, Kanellias N, Christoulas D, Kastritis E, Dimopoulos MA. Pomalidomide: a
novel drug to treat relapsed and refractory multiple myeloma. OncoTargets & Therapy
2013;6:531-8.
82. Terpos E, Morgan G, Dimopoulos MA, Drake M, Lentzsch S, Raje N, Sezer O, GarcíaSanz R, Shimizu K, Turesson I, Reiman T, Jurczyszyn A, Merlini G, Spencer A, Leleu X,
Cavo M, Munsi N, Rajkumar V, Durie BGM, Roodman GD, on behalf of the International
Myeloma Working Group. International Myeloma Working Group recommendations for
the treatment of multiple myeloma related bone disease. Journal of Clinical Oncology
2013;31:2347-57.
14
83. Regelink JC, Minnema MC, Terpos E, Kamphuis MH, Raijmakers PG, Pieters-van den
Bos IC, Heggelman BG, Nievelstein RJ, Otten RH, van Lammeren-Venema D, Zijlstra
JM, Arens AI, de Rooy JW, Hoekstra OS, Raymakers R, Sonneveld P, Ostelo RW,
Zweegman S. Comparison of modern and conventional imaging techniques in
establishing multiple myeloma-related bone disease: a systematic review. British Journal
of Haematology 2013;162:50-61.
84. Terpos E, Apperley JF, Milojkovic D. Imatinib and Chronic Myeloid Leukemia: close to
the bone. Leukemia & Lymphoma 2013;54:1581-2.
85. Kastritis E, Terpos E, Dimopoulos MA. Current treatments for renal failure due to
multiple myeloma. Expert Opinion on Pharmacotherapy 2013;14:1477-95.
86. Terpos E, Christoulas D. Effects of proteasome inhibitors on bone cancer. BoneKey
Reports 2013;2:395 (1-5).
87. Dimopoulos MA, Terpos E, Niesvizky R. How lenalidomide is changing the treatment of
patients with multiple myeloma. Critical Reviews in Oncology/Hematology 2013;88 Suppl
1:S23-35.
88. Dimopoulos MA, Kastritis E, Terpos E. Non-secretory myeloma: one, two, or more
entities? Oncology 2013;27:930-2.
89. Terpos E, Christoulas D, Kastritis E, Dimopoulos MA. Angiogenic cytokines levels in
Waldenstrom’s Macroglobulinemia: clinical correlations. Current Angiogenesis
2013;2:104-9.
90. Terpos E, Dimopoulos MA. Less strength and more fractures for MGUS bones. Blood
2014;123:603-4.
91. Terpos E, Berenson J, Raje N, Roodman GD. Management of bone disease in multiple
myeloma. Expert Review of Hematology 2014;7:113-25.
92. Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk
N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M,
Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V,
Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A. European Myeloma
Network recommendations on the evaluation and treatment of newly diagnosed patients
with multiple myeloma. Haematologica 2014;99:232-42.
93. Mohty M, Malard F, Mohty B, Savani B, Moreau P, Terpos E. The efects of bortezomib
on bone disease in patients with multiple myeloma. Cancer 2014;120:618-23.
94. Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R, Lentzsch
S, Ming Chen W, Hou J, Jurczyszyn A, Romeril K, Hajek R, Terpos E, Shimizu K,
Joshua D, Hungria V, Rodriguez Morales A, Ben-Yehuda D, Sondergeld P, Zamagni E,
Durie B. International Myeloma Working Group recommendations for global myeloma
care. Leukemia 2014;28:981-92.
95. van de Donk NW, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, Hajek R,
Kleber M, Ludwig H, Morgan G, Musto P, Plesner T, Sezer O, Terpos E, Waage A,
Zweegman S, Einsele H, Sonneveld P, Lokhorst HM. The clinical relevance and
management of monoclonal gammopathy of undetermined significance and related
15
disorders: recommendations from the European Myeloma Network. Haematologica
2014;99:984-96.
96. Dimopoulos MA, Terpos E. Solitary bone plasmacytomas need to flow. Blood
2014;124:1209-10.
97. Terpos E, Kanellias N, Giannopoulos K. Biology and management of mieloma-related
bone disease. Acta Haematologica Polonica 2014;45:107-21.
98. Dimopoulos M, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, GarcíaSanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel
M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA,
Kimby E, Merlini G, Treon SP. Treatment recommendations for patients with
Waldenström's Macroglobulinemia (WM) and related disorders: consensus from the
Seventh International Workshop on WM. Blood 2014;124:1404-11.
99. Zagouri F, Kastritis E, Gavriatopoulou M, Sergentanis TN, Psaltopoulou T, Terpos E,
Dimopoulos MA. Lenalidomide in patients with POEMS syndrome: A systematic review
and pooled analysis. Leukemia & Lymphoma 2014;55:2018-23.
100.
van de Donk NW, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H,
Hajek R, Kleber M, Ludwig H, Morgan G, Musto P, Plesner T, Sezer O, Terpos E,
Waage A, Zweegman S, Einsele H, Sonneveld P, Lokhorst HM.De klinische relevantie en
aanpak van MGUS en MGUS-gerelateerde ziekten: aanbevelingen van het “European
Myeloma Network”. Nederlands Tijdschrift Voor Hematologie 2014;7:302-17.
101.
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar
S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B,
LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O,
Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M,
Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International
Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet
Oncolοgy 2014;15:e538-e548.
102.
Pianko MJ, Terpos E, Roodman GD, Divgi CR, Zweegman S, Hillengass J, Lentzsch
S. Whole-Body Low-Dose Computed Tomography and advanced imaging techniques for
multiple myeloma bone disease. Clinical Cancer Research 2014;20:5888-97.
103.
Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, Raje
N, Sezer O, Zweegman S, Shah J, Badros A, Shimizu K, Moreau P, Chim CS, Lahuerta
JJ, Hou J, Jurczyszyn A, Goldschmidt H, Sonneveld P, Palumbo A, Ludwig H, Cavo M,
Barlogie B, Anderson K, Roodman GD, Rajkumar SV, Durie BG, Terpos E. Role of
Magnetic Resonance Imaging in the management of patients with Multiple Myeloma: a
consensus statement. Journal of Clinical Oncology 2015;33:657-64.
104.
Psaltopoulou T, Sergentanis TN, Sergentanis IN, Karadimitris A, Terpos E,
Dimopoulos MA. Alcohol intake, alcoholic beverage type and multiple myeloma risk: a
meta-analysis on 26 observational studies. Leukemia & Lymphoma 2015;56:1484-501.
105.
Zagouri F, Terpos E, Kastritis E, Dimopoulos MA. An update on the use of
lenalidomide for the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy
2015;16:1865-77.
106.
Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk
NWCJ, Bruno B, Sezer O, Broijl A, Bringhen S, Beksac M, Larocca A, Hajek R, Musto P,
Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, Dimopoulos MA,
16
Palumbo A. European Myeloma Network Guidelines for the management of Multiple
Myeloma-related complications. Haematologica 2015;100:1254-66.
107.
Terpos E, Confavreux CB, Clézardin P. Bone antiresorptive agents in the treatment of
bone metastases associated with solid tumours or multiple myeloma. Bonekey Reports
2015;4:74.
108.
Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A. Clinical characteristics of
patietns with relapsed multiple myeloma. Cancer Treatment Reviews 2015;41:827-35.
109.
Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X,
Johnsen HE, Streetly M, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J,
Turesson I, Zamagni E, Chim J, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S,
Joshua D, Roussel M, O'Gorman P, Terpos E, Dimopoulos M, Moreau P, Anderson K,
Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson P. Management of relapsed
multiple myeloma: Recommendations of the international myeloma working group.
Leukemia 2016; in press.
110.
Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E,
Goldschmidt H, Joshua D, Orlowski RZ, Powles R, Vesole DH, Garderet L, Einsele H,
Palumbo A, Cavo M, Richardson PG, Moreau P, San Miguel J, Rajkumar SV, Durie
BGM, Terpos E. International Myeloma Working Group recommendations for the
diagnosis and management of myeloma-related renal impairment. Journal of Clinical
Oncology 2016; in press.
IV. Original Papers in Peer-reviewed Journals:
1. Meletis J, Michali E, Samarkos M, Konstantopoulos K, Meletis C, Terpos E,
Tsimberidou A, Chandrinou E, Viniou N, Rombos Y, Pangalis GA, Yataganas X,
Loukopoulos D. Detection of "PNH red cell" populations in hematological disorders using
the Sephacryl Gel Test micro typing system. Leukemia and Lymphoma 1997;28:177-82.
2. Meletis J, Samarkos M, Mesogitis S, Meletis C, Mougiou A, Terpos E, Tsimberidou A,
Andreopoulos A, Konstantopoulos K, Loukopoulos D. Severe aplastic anaemia relapsing
during a pregnancy; spontaneous remission following termination. Haematologia
1998;29:147-51.
3. Konstantopoulos K, Terpos E, Prinolakis H, Kanta A, Variami E, Kanellopoulou G,
Vaiopoulos G, Floros A, Androulaki A, Meletis J. Systemic lupus erythematosus
presenting as myelofibrosis. Haematologia 1998;29:153-6.
4. Variami E, Terpos E, Vgenopoulou S, Kanellopoulou G, Meletis J. Inflammatory
pseudotumor of the spleen: a case report and review of the literature. Annals of
Hematology 1999;78:560-3.
5. Terpos E, Athanasiou A, Tsoukala C, Anastasopoulou J, Kyriakidis M, Karafoulidou A.
Thrombophilic factors in patients with Syndrome X. Thrombosis Research 2000;97 5257.
6. Papanikolaou G, Politou M, Terpos E, Fourlemadis S, Sakellaropoulos N, Loukopoulos
D. Hereditary hemochromatosis: HFE mutation analysis in Greeks reveals genetic
heterogeneity. Blood Cells Molecules and Diseases 2000;26:163-8.
7. Terpos E, Angelopoulou MK, Variami E, Meletis JC, Vaiopoulos G. Sjogren's syndrome
associated with multiple myeloma. Annals of Hematology 2000;79:449-51.
17
8. Terpos E, Palermos J, Tsionos K, Anargyrou K, Viniou N, Papassavas P, Meletis J,
Yataganas X. Effect of pamidronate administration on markers of bone turnover and
disease activity in multiple myeloma. European Journal of Haematology 2000;65:331-6.
9. Katsarou O, Terpos E, Patsouris E, Peristeris P, Viniou N, Kapsimali V, Karafoulidou A.
Myelodysplastic features in patients with long-term HIV infection and haemophilia.
Haemophilia 2001;7:47-52.
10. Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A,
Diamanti E, Kalovidouris A, Loutradi A, Loukopoulos D. Bone resorption is increased in
young adults with thalassaemia major. British Journal of Haematology 2001; 112: 36-41.
11. Meletis J, Terpos E, Samarkos M, Meletis C, Konstantopoulos K, Komninaka V,
Apostolidou E, Benopoulou O, Korovesis K, Mavrogianni D, Variami E, Yataganas X,
Loukopoulos D. Detection of CD55 and/or CD59 deficient red cell populations in patients
with aplastic anaemia, myelodysplastic syndromes and myeloproliferative disorders.
Haematologia 2001;31:7-16.
12. Vaiopoulos G, Terpos E, Viniou N, Nodaros K, Rombos J, Loukopoulos D. Behcet's
disease in a patient with chronic myelogenous leukemia under hydroxyurea treatment: a
case report and review of the literature. American Journal of Hematology 2001;66:57-8.
13. Meletis J, Terpos E, Samarkos M, Meletis C, Apostolidou E, Komninaka V, Korovesis K,
Mavrogianni D, Boutsis D, Variami E, Viniou N, Konstantopoulos K, Loukopoulos D.
Detection of CD55- and/or CD59-deficient red cell populations in patients with
lymphoproliferative syndromes. Hematology Journal 2001;2:33-7.
14. Meletis J, Dalekou M, Samarkos M, Papavasiliou E, Meletis C, Konstantopoulos K,
Apostolidou E, Komninaka V, Terpos E, Benopoulou O, Korovesis K, Variami E,
Loukopoulos D. Fetal erythropoiesis after allogeneic bone marrow transplantation
estimated by the peripheral blood erythrocytes containing hemoglobin F (F-cells).
Hematology 2001;5:447-53.
15. Terpos E, Palermos J, Viniou N, Vaiopoulos G, Meletis J, Yataganas X. Pamidronate
increases markers of bone formation in patients with multiple myeloma in plateau phase
under interferon-alpha treatment. Calcified Tissue International 2001;68:285-90.
16. Korkolopoulou P, Apostolidou E, Pavlopoulos PM, Kavantzas N, Vyniou N, Thymara I,
Terpos E, Patsouris E, Yataganas X, Davaris P. Prognostic evaluation of the
microvascular network in myelodysplastic syndromes. Leukemia 2001;15:1369-76.
17. Viniou N, Terpos E, Rombos J, Vaiopoulos G, Nodaros K, Stamatopoulos K, Meletis J,
Yataganas X. Acute myeloid leukemia in a patient with ataxia-telangiectasia: a case
report and review of the literature. Leukemia 2001;15:1668-70.
18. Voskaridou E, Terpos E, Komninaka V, Eftyhiadis E, Mantzourani M, Loukopoulos D.
Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia
major: complete haematological remission under the combination of hydroxyurea and
anagrelide. British Journal of Haematology 2002;116:155-7.
19. Meletis J, Terpos E, Samarkos M, Meletis C, Apostolidou E, Komninaka V, Korovesis K,
Anargyrou K, Benopoulou O, Mavrogianni D, Variami E, Viniou N, Konstantopoulos K.
Detection of CD55- and/or CD59-deficient red cell populations in patients with plasma
cell dyscrasias. International Journal of Hematology 2002;75:40-4.
18
20. Viniou N, Terpos E, Galanopoulos A, Kritikou-Griva E, Akel S, Michalis E, Apostolidou
E, Georgiadou D, Kouraklis A, Parharidou A, Kokkini G, Symeonidis A,
Anagnostopoulos NI, Christakis JI, Tasiopoulou A, Loukopoulos D, Yataganas X for The
Greek MDS Study Group. Treatment of anemia in low-risk myelodysplastic syndromes
with amifostine. In vitro testing of response. Annals of Hematology 2002;81:182-6.
21. Meletis J, Terpos E, Samarkos M, Meletis C, Apostolidou E, Komninaka V, Anargyrou
K, Korovesis K, Mavrogianni D, Variami E, Viniou N, Konstantopoulos K. Red cells with
paroxysmal nocturnal hemoglobinuria-phenotype in patients with acute leukemia.
Hematology 2002;7:69-74.
22. Mavrogianni D, Viniou N, Michali E, Terpos E, Meletis J, Vaiopoulos G, Madzourani M,
Pangalis G, Yataganas X, Loukopoulos D. Leukemogenic risk of hydroxyurea therapy as
a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras
mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients.
International Journal of Hematology 2002;75:394-400.
23. Viniou N, Plata E, Terpos E, Variami E, Meletis J, Vaiopoulos G, Loukopoulos D,
Chatzidimitriou G, Yataganas X. Danazol therapy for thrombocytopenia in patients with
myelodysplastic syndromes. Acta Haematologica 2002;107:234-6.
24. Anargyrou K, Vaiopoulos G, Terpos E, Tsironi M, Konstantopoulos K, Samarkos M,
Meletis J. Low dose melphalan is a treatment option in elderly patients with high risk
myelodysplastic syndrome or secondary acute myeloblastic leukaemia. Haematologia
2002;32:169-73.
25. Terpos E, Mougiou A, Kouraklis A, Chatzivassili A, Michalis E, Giannakoulas N,
Manioudaki E, Lazaridou A, Bakaloudi V, Protopappa M, Liapi D, Grouzi E, Parharidou
A, Symeonidis A, Kokkini G, Laoutaris NP, Vaiopoulos G, Anagnostopoulos NI,
Christakis JI, Meletis J, Bourantas KL, Zoumbos NC, Yataganas X, Viniou NA for The
Greek MDS Study Group. Prolonged administration of erythropoietin increases erythroid
response rate in myelodysplastic syndromes: a phase II trial in 281 patients. British
Journal of Haematology 2002;118:174-80.
26. Korkolopoulou P, Viniou N, Kavantzas N, Patsouris E, Thymara I, Pavlopoulos PM,
Terpos E, Stamatopoulos K, Plata E, Anargyrou K, Androulaki A, Davaris P, Yataganas
X. Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid
leukemia: a morphometric study. Leukemia 2003;17:89-97.
27. Terpos E, Viniou N, de la Fuente J, Meletis J, Voskaridou E, Karkantaris C, Vaiopoulos
G, Palermos J, Yataganas X, Goldman JM, Rahemtulla A. Pamidronate is superior to
ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in
multiple myeloma. European Journal of Haematology 2003;70:34-42.
28. Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, Olavarria E, Goldman
JM, Rahemtulla A. Autologous stem cell transplantation in multiple myeloma: improved
survival in nonsecretory multiple myeloma but lack of influence of age, status at
transplant, previous treatment and conditioning regimen. A single-centre experience in
127 patients. Bone Marrow Transplantation 2003;31:163-70.
29. Akel S, Mavroyanni D, Yataganas X, Terpos E, Meletis J, Anargyrou K, Stavrogianni N,
Pangalis GA, Loukopoulos D, Viniou N. Clonal analysis of granulocyte-monocyte colonyforming unit cells with the human androgen receptor gene in chronic myeloid leukemia.
International Journal of Hematology 2003;77:476-81.
19
30. Kalotychou V, Antonatou K, Tzanetea R, Terpos E, Loukopoulos D, Rombos Y. Analysis
of the A(TA)(n)TAA configuration in the promoter region of the UGT1 A1 gene in Greek
patients with thalassemia intermedia and sickle cell disease. Blood Cells, Molecules and
Diseases 2003;31:38-42.
31. Dimopoulos MA, Pouli A, Zervas K, Grigoraki V, Symeonidis A, Repoussis P, Mitsouli C,
Papanastasiou C, Margaritis D, Tokmaktsis A, Katodritou I, Kokkini G, Terpos E, Vyniou
N, Tzilianos M, Chatzivassili A, Kyrtsonis MC, Panayiotidis P, Maniatis A. Prospective
randomized comparison of vincristine, doxorubicin and dexamethasone administered as
intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in
multiple myeloma. Annals of Oncology 2003;14:1039-44.
32. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N,
Yataganas X, Goldman JM, Rahemtulla A. Soluble receptor activator of nuclear factor
kappa B ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for
a novel prognostic index. Blood 2003;102:1064-9.
33. Terpos E, de la Fuente J, Szydlo R, Hatjiharissi E, Viniou N, Meletis J, Yataganas X,
Goldman JM, Rahemtulla A. Tartrate-resistant acid phosphatase isoform 5b: a novel
serum marker for monitoring bone disease in multiple myeloma. International Journal of
Cancer 2003;106:455-7.
34. Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A. Serum levels
of Macrophage Inflammatory Protein-1 alpha (MIPdisease and survival in patients with Multiple Myeloma. British Journal of Haematology
2003;123:106-9.
35. Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos
D. Pamidronate is an effective treatment for osteoporosis in patients with betathalassaemia. British Journal of Haematology 2003;123:730-7.
36. Terpos E, Samarkos M, Meletis C, Apostolidou E, Tsironi M, Korovesis K, Mavrogianni
D, Viniou N, Meletis J. Unusual association between increased bone resorption and
presence of paroxysmal nocturnal hemoglobinuria-phenotype in multiple myeloma.
International Journal of Haematology 2003;78:344-8.
37. Terpos E, Rahemtulla A. Is ibandronate effective in multiple myeloma? European
Journal of Haematology 2003;71:471-2.
38. Cooke FJ, Terpos E, Boyle J, Rahemtulla A, Rogers TR. Disseminated Aspergillus
terreus infection arising from cutaneous inoculation treated with caspofungin. Clinical
Microbiology and Infection 2003;9:1238-41.
39. Voskaridou E, Terpos E. Bisphosphonate treatment for the management of
osteoporosis in beta-thalassaemia. British Journal of Haematology 2004;125:93-4.
40. Terpos E, Politou M, Szydlo R, Nadal E, Avery S, Olavarria E, Kanfer E, Goldman JM,
Apperley JF, Rahemtulla A. Autologous stem cell transplantation normalizes abnormal
bone remodeling and sRANKL/OPG ratio in patients with multiple myeloma. Leukemia
2004;18:1420-26.
41. Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M, Apperley JF,
Dimopoulos MA, Rahemtulla A. Role of receptor activator of nuclear factor-kappa B
ligand, osteoprotegerin, and macrophage inflammatory protein-1 alpha in monoclonal
gammopathy of undetermined significance. British Journal of Haematology
2004;126:686-9.
20
42. Voskaridou E, Douskou M, Terpos E, Papassotiriou I, Stamoulakatou A, Ourailidis A,
Loutradi A, Loukopoulos D. Magnetic resonance imaging in the evaluation of iron
overload in patients with beta-thalassaemia and sickle cell disease. British Journal of
Haematology 2004; 126: 736-742.
43. Terpos E, Politou M, Rahemtulla A. Tumour lysis syndrome in multiple myeloma after
bortezomib (formerly PS-341) administration. Journal of Cancer Research and Clinical
Oncology 2004;130:623-5.
44. Terpos E, Theocharis S, Panitsas F, Philippidis T, Kotronis E, Karkantaris C.
Autoimmune hemolytic anemia with myelodysplastic features followed by bilateral
adrenal non-Hodgkin lymphoma: a case report and review of the literature. Leukemia &
Lymphoma 2004;45:2333-8.
45. Hatjiharissi E*, Terpos E*, Papaioannou M, Hatjileontis C, Kaloutsi V, Galaktidou G,
Gerotziafas G, Christakis J, Zervas K. The combination of intermediate doses of
thalidomide and dexamethasone reduces bone marrow microvessel density but not serum
levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hematological Oncology 2004;2:159-68. *equal contribution
46. Anagnostopoulos GK, Sakorafas GH, Kostopoulos P, Margantinis G, Tsiakos S, Terpos
E, Pavlakis G, Fortun P, Arvanitidis D. Disseminated colon cancer with severe peripheral
blood eosinophilia and elevated serum levels of interleukine-2, interleukine-3,
interleukine-5, and GM-CSF. Journal of Surgical Oncology 2005;89:273-5.
47. Voskaridou E, Terpos E. Osteoprotegerin to soluble receptor activator of nulear factor
kappa-B ligand (RANKL) ratio is reduces in patients with thalassaemia-related
osteoporosis who receive vitamin D3. European Journal of Haematology 2005;74:359-61.
48. Voskaridou E, Douskou M, Terpos E, Stamoulakatou A, Meletis J, Ourailidis A,
Papassotiriou I, Loukopoulos D. Deferiprone as an oral iron chelator in sickle cell
disease. Annals of Haematology 2005;84:434-40.
49. Mavrogianni D, Tsaftaridis P, Terpos E, Symeonidis A, Galanopoulos A, Papadaki EA,
Zoumbos N, Meletis J, Pangalis GA, Viniou N for the Greek MDS Study Group.
Macrophage Inflammatory Protein-1 alpha (MIP-expressed in a cohort of
patients with myelodysplastic syndromes. European Journal of Haematology 2005;75:856.
50. Politou M, Naresh K, Terpos E, Crawley D, Lampert I, Apperley JF, Rahemtulla A. Antiangiogenic effect of bortezomib (VELCADE®) in patients with multiple myeloma. Acta
Haematologica 2005;114:170-3.
51. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ,
Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig
M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross
NC. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative
disorders. Blood 2005;106:2162-8.
52. Terpos E, Rezvani K, Basu S, Milne AE, Rose PE, Scott GL, Rahemtulla A, Samson D,
Apperley JF. Plasmacytoma relapses in the absence of systemic progression post high
dose therapy for multiple myeloma. European Journal of Hematology 2005;75:376-83.
21
53. Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M, Voskaridou E,
Rahemtulla A, Dimopoulos MA, Zervas K. The combination of intermediate doses of
thalidomide with dexamethasone is an effective treatment for patients with
refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through
the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005;19:1969-76.
54. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou
V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA.
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and
risk factors. Journal of Clinical Oncology 2005;23:8580-7.
55. Pavlakis G, Mountzios G, Terpos E, Leivaditou A, Papadopoulos G, Papasavas P.
Recurrent ovarian cancer metastatic to the sternum, costae and thoracic wall after
prolonged treatment with platinum-based chemotherapy: a case report and review of the
literature. International Journal of Gynecological Cancer 2006;16 Suppl 1:299-303.
56. Politou M, Karadimitris A, Terpos E, Kotsianidis I, Apperley JF, Rahemtulla A. No
evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma
with clinical resistance to Bortezomib. Leukemia Research 2006;30:240-1.
57. Dimopoulos MA, Anagnostopoulos A, Terpos E, Repoussis P, Zomas A, Katodritou E,
Kyrtsonis MC, Delibasi S, Vassou A, Pouli A, Zervas K, Anagnostopoulos N, Maniatis A
on behalf of the Greek Myelom Study Group. Primary treatment with pulsed melphalan,
dexamethasone and thalidomide (MDT) for symptomatic patients with multiple myeloma
75 years of age. Haematologica 2006;91:252-4.
58. O'shea D, Giles C, Terpos E, Perz J, Politou M, Sana V, Naresh K, Lampert I, Samson D,
Narat S, Kanfer E, Olavarria E, Apperley JF, Rahemtulla A. Predictive factors for survival
in myeloma patients who undergo autologous stem cell transplantation: a single-centre
experience in 211 patients. Bone Marrow Transplantation 2006;37:731-7.
59. Terpos E, Anagnostopoulos A, Kastritis E, Bamias A, Tsionos K, Dimopoulos MA.
Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1
alpha (MIP-1α) in Waldenstrom's macroglobulinaemia. British Journal of Haematology
2006;133:301-4.
60. Voskaridou E, Terpos E, Michail S, Hantzi E, Anagnostopoulos A, Margeli A, Simirloglou
D, Loukopoulos D, Papassotiriou I. Early markers of renal dysfunction in patients with
sickle cell/beta thalassemia. Kidney International 2006;69:2037-42.
61. Voskaridou E, Stoupa E, Antoniadou L, Premetis E, Konstantopoulos K, Papassotiriou I,
Terpos E. Osteoporosis and osteosclerosis in sickle cell/β-thalassaemia: the role of the
RANKL/osteoprotegerin axis. Haematologica 2006;91:813-6.
62. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos
LA, Bamia C, Terpos E, Tsionos K, Bamias A. Osteonecrosis of the jaw in patients with
multiple myeloma treated with bisphosphonates: evidence of increased risk after
treatment with zoledronic acid. Haematologica 2006;91:968-71.
63. Kastritis E, Terpos E, Anagnostopoulos A, Xilouri I, Dimopoulos MA. Angiogenetic factors
and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose
therapy and autologous stem cell support. Clinical Lymphoma & Myeloma 2006;7:73-6.
64. Dimopoulos MA, Pouli A, Anagnostopoulos A, Repoussis P, Symeonidis A, Terpos E,
Delimbasi S, Tsolakis F, Economopoulos T, Zervas C. Macrofocal multiple myeloma in
22
young patients: a distinct entity with favorable prognosis. Leukemia & Lymphoma
2006;47:1553-6.
65. Mountzios G, Pavlakis G, Terpos E, Sakorafas G, Revelos K, Bamias A, Nikolaou N,
Papasavas P, Soria JC, Dimopoulos MA. Concurrent development of testicular seminoma
and choriocarcinoma of the superior mediastinum, presented as cervical mass: a case
report and implications about pathogenesis of germ-cell tumours. BMC Clinical Pathology
2006;6:8
66. Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, Krikelis D, Terpos E.
Incidence, risk factors and management of osteonecrosis of the jaw in patients with
multiple myeloma: a single-centre experience in 303 patients. British Journal of
Haematology 2006;134:620-3.
67. Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E,
Kiamouris C, Terpos E. Zoledronic acid is an effective treatment for osteoporosis in
patients with beta-thalassaemia: results from a single-centre, randomized, placebocontrolled trial. Haematologica 2006;91:1193-202.
68. Politou MC, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos MA,
Croucher PI, Terpos E. Serum concentrations of Dickkopf-1 protein are increased in
patients with multiple myeloma and reduced after autologous stem cell transplantation.
International Journal of Cancer 2006;119:1728-31.
69. Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A,
Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI. Bortezomib reduces
serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and
normalises indices of bone remodelling in patients with relapsed multiple myeloma. British
Journal of Haematology 2006;135:688-92.
70. Katodritou E, Speletas M, Pouli A, Tsitouridis J, Zervas K, Terpos E. Successful
treatment of extramedullary plasmacytoma of the carvenous sinus using the combination
of intermediate dose of thalidomide and dexamethasone. Acta Haematologica
2007;117:20-3.
71. Galanopoulos AG, Symeonidis A, Kourakli A, Papadaki EA, Tsaftaridis P, Terpos E,
Aktipi A, Roussou P, Protopappa M, Pappaioannou M, Zikos P, Speletas M, Parcharidou
A, Laoutaris N, Anagnostopoulos NI, Meletis J, Pangalis GA, Zoumbos N, Viniou N.
Prognostic significance of deletion of the long arm of chromosome 20 in patients with
myelodysplastic syndrome (MDS): a study of the Greek MDS Study Group. European
Journal of Haematology 2007;78:89-90.
72. Mountzios G, Dimopoulos MA, Bamias A, Papadopoulos G, Kastritis E, Syrigos K,
Pavlakis G, Terpos E. Abnormal bone remodeling process is due to an imbalance in the
receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in
patients with solid tumors metastatic to the skeleton. Acta Oncologica 2007;46:221-9.
73. Terpos E, Verrou E, Banti A, Kaloutsi V, Lazaridou A, Zervas K. Bortezomib is an
effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis. Leukemia
Research 2007;31:559-62.
74. Katodritou E, Terpos E, Zervas K, Speletas M, Kapetanos D, Kartsios C, Verrou E, Banti
A, Effraimidou S, Christakis J. Hypochromic erythrocytes (%): a reliable marker for
recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in
anemic patients with myeloma and lymphoma. Annals of Hematology 2007;86:369-76.
23
75. Voskaridou E, Tsetsos G, Tsoutsias A, Spyropoulou E, Christoulas D, Terpos E.
Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and
correlation with serum N-terminal pro-brain natriuretic peptide (NT-proBNP)
concentrations. Haematologica 2007;92:738-43.
76. Anagnostopoulos A, Eleftherakis-Papaiakovou V, Zervas K, Kastritis E, Tsionos K,
Bamias A, Meletis J, Dimopoulos MA, Terpos E. Serum concentrations of angiogenic
cytokines in Waldenstrom’s Macroglobulinaemia: the ratio of angiopoietin-1 to
angiopoietin-2 and angiogenin correlate with disease severity. British Journal of
Haematology 2007;137:560-8.
77. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G,
Repoussis P, Symeonidis A, Delimpasi S, Katodritou E, Vervessou E, Michali E, Pouli A,
Gika D, Vassou A, Terpos E, Anagnostopoulos N, Economopoulos T, Pangalis G.
Primary treatment of Waldenstrom Macroglobulinemia with dexamethasone, rituximab,
and cyclophosphamide. Journal of Clinical Oncology 2007;25:3344-9.
78. Zervas K, Mihou D, Katodritou E, Pouli A, Mitsouli Ch, Anagnostopoulos A, Delibasi S,
Kyrtsonis M, Anagnostopoulos N, Terpos E, Zikos P, Maniatis A, Dimopoulos M. VADdoxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results
of a multicenter randomized trial of the Greek Myeloma Study Group. Annals of Oncology
2007;18:1369-75.
79. Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M,
Tassidou A, Xilouri I, Delibasi S, Psimenou E, Mellou S, Terpos E, Nanas J, Dimopoulos
MA. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and
dexamethasone. Haematologica 2007;92:1351-8.
80. Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Bamia C, Pouli A, Baltadakis I, Terpos
E, Kyrtopoulos SA, Sfikakis PP. Melphalan-induced DNA damage in vitro as a predictor
for clinical outcome in multiple myeloma. Haematologica 2007;92:1505-12.
81. Bamias A, Koutsoukou V, Terpos E, Tsiatas ML, Tsitsilonis O, Rodolakis A, Voulgaris Z,
Vlahos G, Antsaklis A, Dimopoulos MA. Correlation of NK T-like CD3+CD56+ cells and
CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced
ovarian cancer: Association with platinum resistance and prognosis in patients receiving
first-line, platinum-based chemotherapy. Gynecologic Oncology 2008;108:421-7.
82. Voskaridou E, Christoulas D, Antoniadou L, Terpos E. Continuous increase in
erythropoietic activity despite the improvement in Bone Mineral Density by zoledronic acid
in patients with thalassemia intermedia-induced osteoporosis. Acta Haematologica
2008;119:40-4.
83. Anargyrou K, Terpos E, Vassilakopoulos TP, Pouli A, Sachanas S, Tzenou T, Masouridis
S, Christoulas D, Angelopoulou MK, Dimitriadou EM, Kalpadakis C, Tsionos K,
Panayiotidis P, Dimopoulos MA, Pangalis GA, Kyrtsonis MC; on behalf of the Greek
Myeloma Study Group. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio
reflects response in refractory/resistant multiple myeloma patients treated with
bortezomib. Haematologica 2008;93:451-4.
84. Zoi K, Terpos E, Zoi C, Loukopoulos D. Increased CD177 (PRV-1) expression in
thalassaemia and the underlying erythropoietic activity. British Journal of Haematology
2008;141:100-4.
24
85. Terpos E, Sezer O. Reply to 'Proteasome inhibition therapies in childhood cancer' by
Zaman et al. Leukemia 2008;22:884-5.
86. Terpos E, Sarantopoulos A, Kouramba A, Katsarou O, Stavropoulos J, Masouridi S,
Karafoulidou A, Meletis J. Reduction of CD55 and/or CD59 in red blood cells of patients
with HIV infection. Medical Science Monitor 2008;14:276-80.
87. Roussou M, Kastritis E, Migkou M, Psimenou E, Grapsa I, Matsouka C, Barmparousi D,
Terpos E, Dimopoulos MA. Treatment of patients with multiple myeloma complicated by
renal failure with bortezomib-based regimens. Leukemia & Lymphoma 2008; 49: 890-5.
88. Pilichou A, Papassotiriou I, Michalakakou K, Fessatou S, Fandridis E, Papachristou G,
Terpos E. High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio
of receptor activator of nuclear factor-kappaB ligand (RANKL) to OPG correlate with
disease severity in patients with primary knee osteoarthritis. Clinical Biochemistry
2008;41:746-9.
89. Katodritou E, Verrou E, Gastari V, Hadjiaggelidou C, Terpos E, Zervas K. Response of
primary plasma cell leukemia to the combination of bortezomib and dexamethasone: Do
specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
Leukemia Research 2008;32:1153-6.
90. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE.
Normalization of bone markers is associated with improved survival in patients with bone
metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
Cancer 2008;113:193-201.
91. Badros A, Goloubeva O, Terpos E, Milliron T, Baer MR, Streeten E. Prevalence and
significance of vitamin D deficiency in multiple myeloma patients. British Journal of
Haematology 2008;142:492-4.
92. Katodritou E, Verrou E, Hadjiaggelidou C, Gastari V, Laschos K, Kontovinis L, Kapetanos
D, Constantinou N, Terpos E, Zervas K. Erythropoiesis stimulating agents are associated
with reduced survival in patients with multiple myeloma. American Journal of Hematology
2008;83:697-701.
93. Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E.
Continuous improvement of bone mineral density two years post zoledronic acid
discontinuation in patients with thlassemia-induced osteoporosis: long-term follow-up of a
randomized, placebo-controlled trial. Haematologica 2008;93:1588-90.
94. Katsarou O, Theodosiades G, Ioannidou P, Nomikou E, Tsevrenis V, Kouraba A, Deutch
M, Terpos E, Dourakis S, Karafoulidou A. Pegylated interferon and ribavirin combination
therapy for chronic hepatitis C in patients with congenital coagulation disorders. Acta
Haematologica 2008;120:120:63-9.
95. Badros A, Terpos E, Katodritou E, Goloubeva O, Kastritis E, Verrou E, Zervas K, Baer
MR, Meiller T, Dimopoulos MA. The natural history of osteonecrosis of the jaw in multiple
myeloma patients. Journal of Clinical Oncology 2008;26:5904-9.
96. Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N,
Eleftherakis-Papaiakovou E, Tsionos K, Croucher P, Dimopoulos MA. The combination of
bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective
regimen for relapsed/refractory myeloma and is associated with improvement of abnormal
bone metabolism and angiogenesis. Leukemia 2008;22:2247-56.
25
97. Kastritis E, Katoulis A, Terpos E, Panayiotides I, Gavriatopoulou M, Dimopoulos MA.
Schnitzler’s syndrome: increased levels of bone formation and angiogenesis factors are
reduced following successful pefloxacine treatment. Clinical Lymphoma & Myeloma
2008;8:359-62.
98. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou Maria, Migkou M,
Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Βamias A. Reduction of
osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients
with multiple myeloma treated with zoledronic acid. Annals of Oncology 2009;20:117-20.
99. von Metzler I, Krebbel H, Kuckelkorn U, Heider U, Jakob C, Kaiser M, Fleissner C,
Terpos E, Sezer O. Curcumin diminishes human osteoclastogenesis by inhibition of the
signalosome-associated I-κB kinase. Journal of Cancer Research & Clinical Oncology
2009;135:173-9.
100. Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Christoulas D, Pouli A, Michalis E,
Verrou E, Anargyrou K, Tsionos K, Dimopoulos MA, Zervas K on behalf of the Greek
Myeloma Study Group. Cystatin-C is an independent prognostic factor for survival in
multiple myeloma and is reduced by bortezomib monotherapy. Haematologica
2009;94:372-9.
101. Spanoudakis E, Hu M, Naresh K, Terpos E, Melo V, Reid A, Kotsianidis I, Rahemtulla
A, Karadimitris A. Regulation of multiple myeloma survival and progression by CD1d.
Blood 2009;113:2498-507.
102. Voskaridou E, Christoulas D, Xirakia C, Varvagiannis K, Boutsikas G, Bilalis A,
Kastritis E, Papatheodorou A, Terpos E. Serum dickkopf-1 is increased and correlates
with reduced Bone Mineral Density in patients with Thalassemia-induced osteoporosis.
Reduction post-zoledronic acid administration. Haematologica 2009;94:725-8.
103. Terpos E, Kiagia M, Karapanagiotou EM, Charpidou A, Dilana KD, Nasothimiou E,
Harrington KJ, Polyzos A, Syrigos KN. The clinical significance of serum markers of bone
turnover in NSCLC patients: surveillance, management and prognostic implications.
Anticancer Research 2009;29:1651-7.
104. Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N,
Michali E, Zomas A, Katodritou I, Gika D, Pouli A, Christoulas D, Roussou M, Kartasis Z,
Economopoulos T, Dimopoulos MA. Improved survival of patients with multiple myeloma
after the introduction of novel agents and the applicability of the International Staging
System (ISS): An analysis of the Greek Myeloma Study Group (GMSG). Leukemia
2009;23:1152-57.
105. Anastasilakis AD, Polyzos SA, Avramidis A, Papatheodorou A, Terpos E. Effect of
strontium ranelate on lumbar spine Bone Mineral Density in women with established
osteoporosis previously treated with teriparatide. Hormone & Metabolic Research
2009;41:559-62.
106. Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE. Natural history of
malignant bone disease in breast cancer and the use of cumulative mean functions to
measure skeletal morbidity. BMC Cancer 2009;9:272.
107. Katodritou E, Ganz T, Terpos E, Verrou E, Oblina G, Gastari V, Hadjiaggelidou C,
Varthaliti M, Georgiadou S, Westerman M, Zervas K. Sequential evaluation of serum
hepcidin in anemic myeloma patients: study of correlations with myeloma treatment,
26
disease variables, and anemia response. American Journal of Hematology 2009;84:5246.
108. Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C,
Barbarousi D, Christoulas D, Primenou E, Grapsa I, Terpos E, Kastritis E. Reversibility of
renal impairment of multiple myeloma patients treated with bortezomib-based regimens:
Identification of predictive factors. Clinical Lymphoma & Myeloma 2009;9:302-6.
109. Polyzos SA, Anastasilakis AD, Terpos E. Transient secondary hyperparathyroidism
following intravenous infusion of zoledronic acid. Supportive Care in Cancer
2009;17:1329-30.
110. Polyzos SA, Anastasilakis AD, Efstathiadou Z, Kita M, Litsas I, Avramidis A, Arsos G,
Moralidis E, Gerou S, Pavlidou V, Papatheodorou A, Terpos E. The effect of zoledronic
acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease
of bone. Hormone & Metabolic Research 2009;41:846-50.
111. Roussou M, Tasidou A, Dimopoulos MA, Kastritis E, Migkou M, Christoulas D,
Gavriatopoulou M, Zagouri F, Matsouka C, Anagnostou D, Terpos E. Increased
expression of macrophage inflammatory protein-1
extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed
patients with multiple myeloma. Leukemia 2009;23:2177-81.
112. Jakob C, Goerke A, Terpos E, Sterz J, Heider U, Kühnhardt D, Ziefle S, Kleeberg L,
Mieth M, Metzler I, Müller C, Sezer O. Serum levels of total RANKL in multiple myeloma.
Clinical Lymphoma & Myeloma 2009;9:430-5.
113. Voskaridou E, Plata E, Douskou M, Papadakis M, Delaki EE, Christoulas D, Terpos E.
Treatment with deferasirox (Exjade®) effectively decreases iron burden in patients with
thalassaemia intermedia: results of a pilot study. British Journal of Haematology
2010;148:332-4.
114. Katsarou O, Terpos E, Chatzismalis P, Provelengios S, Adraktas T, Hadjidakis D,
Kouramba A, Karafoulidou A. Increased bone resorption is implicated in the pathogenesis
of bone loss in hemophiliacs: correlations with hemophilic arthropathy and HIV infection.
Annals of Hematology 2010;89:67-74.
115. Bozas G, Terpos E, Gika D, Karadimou A, Dimopoulos MA, Bamias A.
Prechemotherapy serum levels of CD105, Transforming Growth Factor beta2, and
Vascular Endothelial Growth Factor are associated with prognosis in patients with
advanced epithelial ovarian cancer treated with cytoreductive surgery and platinumbased chemotherapy. International Journal of Gynecological Cancer 2010;20:248-54.
116. Terpos E, Dimopoulos MA, Shrivastava V, Leitzel K, Christoulas D, Migkou M,
Gavriatopoulou M, Anargyrou K, Hamer P, Kastritis E, Carney W, Lipton A. High levels of
serum TIMP-1 correlate with advanced disease and predict for poor survival in patients
with multiple myeloma treated with novel agents. Leukemia Research 2010;34:399-402.
117. Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G,
Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E. The effect of prolonged
administration of hydroxyurea on morbidity and mortality in adult patients with sickle-cell
syndromes: results of a 17-year, single center trial (LaSHS). Blood 2010;115:2354-63.
118. Polyzos SA, Anastasilakis AD, Litsas I, Sapranidis M, Efstathiadou Z, Kita M, Arsos G,
Moralidis E, Zafeiriadou E, Papatheodorou A, Terpos E. Dual-Energy X-Ray
Absorptiometry and Quantitative Ultrasound in patients with Paget's disease of bone
27
before and after treatment with zoledronic acid: association with serum bone markers and
dickkopf-1. Journal of Clinical Densitometry 2010;13:190-196.
119. Tsagarakis NJ, Kentrou NA, Papadimitriou KA, Pagoni M, Kokkini G, Papadaki H,
Pappa V, Marinakis T, Anagnostopoulos NI, Vadikolia C, Anagnostopoulos A,
Angelopoulou MK, Terpos E, Poziopoulos C, Anargyrou K, Rontogianni D, Papadaki T,
Psarra A, Kontopidou FN, Skoumi D, Papadhimitriou SI, Paterakis G. Acute
lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell
Leukemia Study Group. Leukemia Research 2010; 34:438-446.
120. Terpos E, Berenson J, Cook RJ, Lipton A, Coleman RE. Prognostic variables for
survival and skeletal complications in patients with multiple myeloma osteolytic bone
disease. Leukemia 2010;24:1043-1049.
121. Mountzios G, Terpos E, Syrigos K, Papadimitriou C, Papadopoulos G, Bamias A,
Mavrikakis M, Dimopoulos MA. Markers of bone remodeling and skeletal morbidity in
patients with solid tumors metastatic to the skeleton receiving the biphosphonate
zoledronic acid. Translational Research 2010;155:247-255.
122. Polyzos SA, Anastasilakis AD, Efstathiadou Z, Litsas I, Kita M, Panagiotou A,
Papatheodorou A, Arsos G, Moralidis E, Barmpalios G, Zafeiriadou E, Triantafillidou E,
Makrigiannaki E, Terpos E. Serum homocysteine, folate and vitamin B12 in patients with
Paget's disease of bone: the effect of zoledronic acid. Journal of Bone & Mineral
Metabolism 2010;28:314-319.
123. Karapanagiotou EM, Terpos E, Dilana KD, Alamara C, Gkiozos I, Polyzos A, Syrigos
KN. Serum bone turnover markers may be involved in the metastatic potential of lung
cancer patients. Medical Oncology 2010;27:332-338.
124. Moulopoulos LA, Dimopoulos MA, Christoulas D, Kastritis E, Anagnostou D, Koureas
A, Roussou M, Gavriatopoulou M, Migkou M, Iakovaki M, Gkotzamanidou M, Tasidou A,
Terpos E. Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced
disease features and poor prognosis in newly diagnosed myeloma treated with novel
agents. Leukemia 2010;24:1206-1212.
125. Anastasilakis AD, Polyzos SA, Avramidis A, Toulis KA, Papatheodorou A, Terpos E.
The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with
established osteoporosis. Clinical Endocrinology 2010;72:752-757.
126. Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M,
Matsouka C, Mparmparoussi D, Psimenou E, Grapsa I, Efstathiou E, Terpos E.
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple
myeloma: dosing of lenalidomide according to renal function and effect on renal
impairment. European Journal of Haematology 2010;85:1-5.
127. Terpos E, Christoulas D, Kokkoris P, Anargyrou K, Gavriatopoulou M, Migkou M,
Tsionos K, Dimopoulos MA. Increased bone mineral density in a subset of patients with
relapsed multiple myeloma who received the combination of bortezomib, dexamethasone
and zoledronic acid. Annals of Oncology 2010;21:1561-1562.
128. Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E, Delimpasi S, Parharidou A,
Kartasis Z, Zomas A, Symeonidis A, Viniou NA, Anagnostopoulos N, Economopoulos T,
Zervas K, Dimopoulos MA. High serum lactate dehydrogenase adds prognostic value to
the International Myeloma Staging System even in the era of novel agents. European
Journal of Haematology 2010;85:114-119.
28
129. Kastritis E, Roussou M, Michael M, Gavriatopoulou M, Michalis E, Migkou M,
Delimpasi S, Kyrtsonis MC, Gogos D, Liapis K, Charitaki E, Repousis P, Terpos E,
Dimopoulos MA. High levels of serum angiogenic growth factors in patients with AL
amyloidosis: comparisons with normal individuals and multiple myeloma patients. British
Journal of Haematology 2010;150:587-591.
130. Kastritis E, Kyrtsonis MC, Hadjiharissi E, Symeonidis A, Michalis E, Repoussis P,
Tsatalas C, Michael M, Sioni A, Kartasis Z, Stefanoudaki E, Voulgarelis M, Delimpasi S,
Gavriatopoulou M, Koulieris E, Gika D, Zomas A, Roussou P, Anagnostopoulos N,
Economopoulos T, Terpos E, Zervas K, Dimopoulos MA; on behalf of the Greek
Myeloma Study Group. Validation of the International Prognostic Scoring System (IPSS)
for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate
dehydrogenase (LDH). Leukemia Research 2010;34:1340-1343.
131. Roussou M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Grapsa I,
Psimenou E, Gika D, Terpos E, Dimopoulos MA. Reversibility of renal failure in newly
diagnosed patients with multiple myeloma and the role of novel agents. Leukemia
Research 2010;34:1395-1397.
132. Boskos CS, Liacos C, Korkolis D, Aygerinos K, Lamproglou
Baltatzis G, Beroukas K, Papasavvas P, Dimopoulos MA,
phosphorylase to dihydropyrimidine dehydrogenase ratio as
response to preoperative chemoradiation with capecitabine in
rectal cancer. Journal of Surgical Oncology 2010;102:408-412.
I, Terpos E, Stoupa E,
Bamias A. Thymidine
a predictive factor of
patients with advanced
133. Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M,
Gkotzamanidou M, Iakovaki M, Matsouka C, Mparmparoussi B, Roussou M, Efstathiou E,
Terpos E. Treatment of patients with relapsed/refractory multiple myeloma with
lenalidomide and dexamethasone with or without bortezomib: Prospective evaluation of
the impact of cytogenetic abnormalities and of prior therapies. Leukemia 2010;24:17691778.
134. Polyzos SA, Anastasilakis AD, Litsas I, Efstathiadou Z, Kita M, Arsos G, Moralidis E,
Papatheodorou A, Terpos E. Profound hypocalcemia following effective response to
zoledronic acid treatment in a patient with juvenile Paget's disease. Journal of Bone &
Mineral Metabolism 2010;28:706-712.
135. Eleutherakis-Papaiakovou E, Kostis E, Migkou M, Christoulas D, Terpos E,
Gavriatopoulou M, Roussou M, Bournakis E, Kastritis E, Efstathiou E, Dimopoulos MA,
Papadimitriou CA. Prophylactic antibiotics for the prevention of neutropenic fever in
patients undergoing autologous stem-cell transplantation: Results of a single institution,
randomized phase 2 trial. American Journal of Hematology 2010;85:863-867.
136. Voskaridou E, Plata E, Douskou M, Sioni A, Mpoutou E, Christoulas D, Dimopoulou M,
Terpos E. Deferasirox effectively decreases iron burden in patients with double
heterozygous HbS/beta-thalassemia. Annals of Hematology 2011;90:11-15.
137. Polyzos SA, Kountouras J, Anastasilakis AD, Litsas I, Kita M, Arsos G, Moralidis E,
Terpos E. Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated
for Paget's disease of bone. Osteoporosis International 2011;22:363-367.
138. Skliris A, Happonen KE, Terpos E, Labropoulou V, Børset M, Heinegård D, Blom AM,
Theocharis AD. Serglycin inhibits the classical and lectin pathways of complement by
binding C1q and mannose-binding lectin. European Journal of Immunology 2011;41:43749.
29
139. Terpos E, Tasidou A, Eleftherakis-Papaiakovou E, Christoulas D, Gavriatopoulou M,
Gkotzamanidou M, Roussou M, Kastritis E, Papadaki T, Dimopoulos MA. Expression of
CCL3 by neoplastic cells in patients with Waldenström's Macroglobulinemia: an
immunohistochemical study in bone marrow biopsies of 67 patients. Clinical Lymphoma
Myeloma & Leukemia 2011;11:115-117.
140. Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Michael M, Hadjiharissi E, Symeonidis A,
Michalis E, Repoussis P, Tsatalas K, Sioni A, Kartasis Z, Stefanoudaki E, Voulgarelis M,
Delimpasi S, Gika D, Vervesou E, Konstantopoulos K, Kokkini G, Zomas A, Roussou P,
Anagnostopoulos N, Economopoulos T, Terpos E, Zervas K, Dimopoulos MA.
Prognostication of the high-risk WM patient. Clinical Lymphoma Myeloma & Leukemia
2011;11:127-129.
141. Grass S, Preuss KD, Wikowicz A, Terpos E, Ziepert M, Fadle N, Regitz E,
Dimopoulos MA, Treon SP, Hunter ZR, Pfreundschuh M. Hyperphosphorylated paratarg7: A new molecularly defined risk factor for monoclonal gammopathy of undetermined
significance of the IgM type (IgM-MGUS) and Waldenstrom's macroglobulinemia (WM).
Blood 2011;117:2918-2923.
142. Delforge M, Terpos E, Richardson PG, Shpilberg O, Khuageva NK, Schlag R,
Dimopoulos MA, Kropff M, Spicka I, Petrucci MT, Samoilova OS, Mateos MV, MagenNativ H, Goldschmidt H, Esseltine DL, Ricci DS, Liu K, Deraedt W, Cakana A, van de
Velde H, San Miguel JF. Fewer bone disease events, improvement in bone remodelling,
and evidence of bone healing with bortezomib plus melphalan-prednisone versus
melphalan-prednisone, in the phase III VISTA trial in multiple myeloma. European
Journal of Haematology 2011;86:372-384.
143. Kastritis E, Kyrtsonis MC, Hatjiharissi E, Symeonidis A, Michalis E, Repoussis P,
Tsatalas K, Michael M, Sioni A, Kartasis Z, Stefanoudaki E, Voulgarelis M, Delimpasi S,
Gavriatopoulou M, Koulieris E, Gika D, Vervesou E, Konstantopoulos K, Kokkini G,
Zomas A, Roussou P, Anagnostopoulos N, Economopoulos T, Terpos E, Zervas K,
Dimopoulos MA. No significant improvement in the outcome of patients with
Waldenström's macroglobulinemia treated over the last 25 years. American Journal of
Hematology 2011;86(6):479-83.
144. Voskaridou E, Christoulas D, Terpos E. Successful chelation therapy with the
combination of deferasirox and deferiprone in a patient with thalassaemia major and
persisting severe iron overload after single-agent chelation therapies. British Journal of
Haematology 2011;154:654-6.
145. Zagouri F, Roussou M, Kastritis E, Koureas A, Tsokou E, Migkou M, Gavriatopoulou
M, Nikitas N, Gkotzamanidou M, Terpos E, Dimopoulos MA. Lenalidomide-associated
pneumonitis in patients with plasma cell dyscrasias. American Journal of Hematology
2011;86:882-4.
146. Migkou M, Kastritis E, Roussou M, Gkotzamanidou M, Gavriatopoulou M, Nikitas N,
Mparmparoussi D, Matsouka C, Gika D, Terpos E, Dimopoulos MA. Short progression
free survival predicts for poor overall survival in older patients with multiple myeloma
treated upfront with novel agent-based therapy. European Journal of Haematology
2011;87:323-9.
147. Such E, Cervera J, Terpos E, Bagan JV, Avaria A, Gomez I, Margaix M, Ibanez M,
Luna I, Cordon L, Roig M, Sanz MA, Dimopoulos MA, de la Rubia J. CYP2C8 gene
polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with
multiple myeloma. Haematologica 2011;96:1557-9.
30
148. Gkotzamanidou M, Kastritis E, Gavriatopoulou MR, Nikitas N, Gika D, Mparmparousi
D, Matsouka C, Terpos E, Dimopoulos MA. Increased serum lactate dehydrongenase
should be included among the variables that define very high-risk multiple myeloma.
Clinical Lymphoma Myeloma & Leukemia 2011;11:409-13.
149. Giannakoulas NC, Terpos E, Palassopoulou M, Zolota V, Lampropoulou P,
Symeonidis A, Matsouka P. Increased RANKL and IL-6 levels might result in high bone
turnover in a case of a CD34(+)/CD117(+)/myeloperoxidase(+dim) acute myeloid
leukemia presenting with severe hypercalcemia and lumbar spine fractures. Leukemia
Research 2011;35:e188-9.
150. Migkou M, Gkotzamanidou M, Terpos E, Dimopoulos MA, Kastritis E. Response to
bortezomib of a patient with scleromyxedema refractory to other therapies. Leukemia
Research 2011;35:e209-11.
151. Terpos E, Fragiadaki K, Konsta M, Bratengeier C, Papatheodorou A, Sfikakis PP.
Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with
rheumatoid arthritis. Clinical & Experimental Rheumatology 2011;29:921-5.
152. Katodritou E, Terpos E, North J, Kottaridis P, Verrou E, Gastari V, Chadjiaggelidou
C, Sivakumaran S, Jide-Banwo S, Tsirogianni M, Kapetanos D, Zervas K, Lowdell MW.
Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous,
NK-resistant, bone marrow-derived malignant plasma cells. American Journal of
Hematology 2011;86:967-73.
153. Eleftherakis-Papaiakovou E, Kastritis E, Roussou M, Gkotzamanidou M, Grapsa I,
Psimenou E, Nikitas N, Terpos E, Dimopoulos MA. Renal impairment is not an
independent adverse prognostic factor in patients with multiple myeloma treated upfront
with novel agent-based regimens. Leukemia & Lymphoma 2011;52:2299-303.
154. Makras P, Polyzos SA, Anastasilakis AD, Terpos E, Papatheodorou A, Kaltsas GA.
Is Serum IL-17A a Useful Systemic Biomarker in Patients With Langerhans Cell
Histiocytosis? Molecular Therapy 2012;20:6-7.
155. Terpos E, Anargyrou K, Katodritou E, Kastritis E, Papatheodorou A, Christoulas D,
Pouli A, Michalis E, Delimpasi S, Gkotzamanidou M, Nikitas N, Koumoustiotis V,
Margaritis D, Tsionos K, Stefanoudaki E, Meletis J, Zervas K, Dimopoulos MA.
Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for
survival in newly diagnosed patients with multiple myeloma who received therapy with
novel anti-myeloma agents. International Journal of Cancer 2012;130:735-42.
156. Ziogas AC, Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Terpos E, Rodolakis A,
Vlahos G, Thomakos N, Haidopoulos D, Antsaklis A, Dimopoulos MA, Bamias A. VEGF
directly suppresses activation of T cells from ovarian cancer patients and healthy
individuals via VEGF receptor type 2. International Journal of Cancer 2012;130:857-64.
157. Vassilakopoulos TP, Pangalis GA, Katsigiannis A, Papageorgiou SG, Constantinou
N, Terpos E, Zorbala A, Vrakidou E, Repoussis P, Poziopoulos C, Galani Z,
Dimopoulou MN, Kokoris SI, Sachanas S, Kalpadakis C, Dimitriadou EM, Siakantaris
MP, Kyrtsonis MC, Dervenoulas J, Dimopoulos MA, Meletis J, Roussou P, Panayiotidis
P, Beris P, Angelopoulou MK. Rituximab, cyclophosphamide, Doxorubicin, vincristine,
and prednisone with or without radiotherapy in primary mediastinal large B-cell
lymphoma: the emerging standard of care. Oncologist 2012;17:239-49.
158. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A,
Terpos E. Serum sclerostin levels positively correlate with lumbar spinal bone mineral
31
density in postmenopausal women – The six-month effect of risedronate and
teriparatide. Osteoporosis International 2012;23:1171-6.
159. Dimopoulos MA, Kastritis E, Michalis E, Tsatalas C, Michael M, Pouli A, Kartasis Z,
Delimpasi S, Gika D, Zomas A, Roussou M, Konstantopoulos K, Parcharidou A, Zervas
K, Terpos E. The International Scoring System (ISS) for multiple myeloma remains a
robust prognostic tool independently of patients' renal function. Annals of Oncology
2012;23:722-9.
160. Makras P, Polyzos SA, Anastasilakis AD, Terpos E, Kanakis G, Schini M,
Papatheodorou A, Kaltsas GA. Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in
Adults with Langerhans Cell Histiocytosis. Journal of Clinical Endocrinology &
Metabolism 2012;97(4):E618-21.
161. Makras P, Terpos E, Kanakis G, Papatheodorou A, Anastasilakis AD, Kokkoris P,
Kaltsas GA. Reduced bone mineral density in adult patients with Langerhans cell
histiocytosis. Pediatric Blood & Cancer 2012;58:819-22.
162. Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I,
Marinaki S, Apostolou T, Nikitas N, Gkortzolidis G, Michalis E, Delimpasi S, Dimopoulos
MA. A phase I/II study of lenalidomide with low dose oral cyclophosphamide and low
dose dexamethasone (RdC) in AL amyloidosis. Blood 2012;119:5384-90.
163. Dimopoulos MA, Kastritis E, Delimpasi S, Katodritou E, Hatzimichael E, Kyrtsonis
MC, Repousis P, Tsirogianni M, Kartasis Z, Parcharidou A, Michael M, Michalis E,
Tsatalas C, Stefanoudaki E, Hatjiharissi E, Gika D, Symeonidis A, Terpos E, Zervas K.
Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent
era. European Journal of Haematology 2012;89:10-5.
164. Tasidou A, Roussou M, Terpos E, Kastritis E, Gkotzamanidou M, Gavriatopoulou M,
Migkou M, Eleutherakis-Papaiakovou E, Nikitas N, Anagnostou D, Dimopoulos MA.
Increased expression of cyclin-D1 on trephine bone marrow biopsies independently
predicts for shorter overall survival in patients with multiple myeloma treated with novel
agents. American Journal of Hematology 2012;87:734-6.
165. Moulopoulos LA, Dimopoulos MA, Kastritis E, Christoulas D, Gkotzamanidou M,
Roussou M, Koureas A, Migkou M, Gavriatopoulou M, Eleutherakis-Papaiakovou E,
Gika D, Koutoulidis V, Terpos E. Diffuse pattern of bone marrow involvement on
Magnetic Resonance Imaging is associated with high risk cytogenetics and poor
outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single
center experience on 228 patients. American Journal of Hematology 2012;87:861-4.
166. Polyzos SA, Anastasilakis AD, Anagnostis P, Kita M, Arsos G, Moralidis E,
Papatheodorou A, Terpos E. Normal bone turnover markers in a patient with active
Paget's disease of bone: response to treatment with zoledronic acid. Endokrynologia
Polska 2012;63:312-5.
167. Terpos E, Christoulas D, Katodritou E, Bratengeier C, Gkotzamanidou M, Michalis
E, Delimpasi S, Pouli A, Meletis J, Kastritis E, Zervas K, Dimopoulos MA. Elevated
circulating sclerostin correlates with advanced disease features and abnormal bone
remodeling in symptomatic myeloma; reduction post-bortezomib monotherapy.
International Journal of Cancer 2012;131:1466-71.
168. Terpos E, Kastritis E, Christoulas D, Gkotzamanidou M, Eleutherakis-Papaiakovou
E, Kanellias N, Papatheodorou A, Dimopoulos MA. Circulating activin-A is elevated in
patients with advanced multiple myeloma, correlates with extensive bone involvement
32
and inferior survival; no alterations post-lenalidomide and dexamethasone therapy.
Annals of Oncology 2012;23:2681-6.
169. Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Ioannou K, Ziogas AC, Rodolakis A,
Vlahos G, Thomakos N, Haidopoulos D, Terpos E, Antsaklis A, Dimopoulos MA,
Bamias A. VEGF directly suppresses activation of T cells from ascites secondary to
ovarian cancer via VEGF receptor type 2. British Journal of Cancer 2012;107:1869-75.
170. Terpos E, Asli B, Christoulas D, Brouet JC, Kastritis E, Rybojad M, Bengoufa D,
Dimopoulos MA, Fermand JP. Increased angiogenesis and enhanced bone formation in
patients withIGM monoclonal gammopathy and urticarial skin rash: new insight intothe
biology of the Schnitzler syndrome. Haematologica 2012;97:1699-703.
171. Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka
V, Kaliontzi D, Gkotzamanidou M, Polyzos SA, Dimopoulou M, Terpos E. High
circulating sclerostin is present in patients with thalassemia-associated osteoporosis and
correlates with bone mineral density. Hormone & Metabolic Research 2012;44:909-13.
172. Polyzos SA, Kountouras J, Zavos C, Papatheodorou A, Katsiki E, Patsiaoura K,
Zafeiriadou E, Michael S, Terpos E. Serum ferritin in patients with non-alcoholic fatty
liver disease: evaluation of ferritin to adiponectin ratio and ferritin by homeostatic model
of assessment insulin resistance product as non-invasive markers. ImmunoGastroenterology 2012;1-2:119-125.
173. Kyrtsonis M-C, Koulieris E, Maltezas D, Tzenou T, Harding S, Kastritis E, Kafassi N,
Bartzis V, Efthymiou A, Bitsanis K, Gavriatopoulou M, Terpos E, Kalpadakis C,
Angelopoulou MK, Vassilakopoulos TP, Bradwell AR, Beris Ph, Pangalis GA,
Panayiotidis P, Dimopoulos MA. Prognostic contribution of the new immunoglobulin (Ig)
biomarkers (FreeliteTM and HevyliteTM) in Waldenstrom’s Macroglobulinemia (WM).
American Journal of Medicine and Medical Sciences 2012;2:136-143.
174. Chaidos A, Barnes CP, Cowan G, May PC, Melo V, Hatjiharissi E, Papaioannou M,
Harrington H, Doolittle H, Terpos E, Dimopoulos M, Abdalla S, Yarranton H, Naresh K,
Foroni L, Reid A, Rahemtulla A, Stumpf M, Roberts I, Karadimitris A. Clinical drug
resistance linked to interconvertible phenotypic and functional states of tumorpropagating cells in multiple myeloma. Blood 2013;121:318-28.
175. Polyzos SA, Kountouras J, Papatheodorou A, Patsiaoura K, Katsiki E, Zafeiriadou E,
Zavos C, Anastasiadou K, Terpos E. Helicobacter pylori infection in patients with
nonalcoholic fatty liver disease. Metabolism 2013;62:121-6.
176. Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E,
Mparmparoussi D, Matsouka C, Spyropoulou-Vlachou M, Terpos E, Kastritis E. The role
of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic
patients with multiple myeloma. Leukemia 2013;27:423-9.
177. Kastritis E, Terpos E, Moulopoulos L, Spyropoulou-Vlachou M, Kanellias N,
Eleftherakis-Papaiakovou E, Gkotzamanidou M, Migkou M, Gavriatopoulou M, Tasidou
A, Dimopoulos MA. Extensive bone marrow infiltration and abnormal free light chain ratio
identifies patients with asymptomatic myeloma at high risk for progression to
symptomatic disease. Leukemia 2013;27:947-53.
178. Polyzos SA, Anastasilakis AD, Terpos E. Serum sclerostin levels following treatment
with parathyroid hormone. Journal of Endocrinological Investigation 2013;36:280.
33
179. Maltezas D, Dimopoulos MA, Katodritou I, Repousis P, Pouli A, Terpos E,
Panayiotidis P, Delimpasi S, Michalis E, Anargyrou K, Gavriatopoulou M, Stefanoudaki
A, Tzenou T, Koulieris E, Sachanas S, Dimou M, Vassilakopoulos TP, Angelopoulou
MK, Pangalis GA, Kyrtsonis MC. Re-evaluation of prognostic markers including staging,
serum free light chains or their ratio and serum lactate dehydrogenase in multiple
myeloma patients receiving novel agents. Hematological Oncology 2013;31:356-62.
180. Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Savvides M, Papatheodorou A,
Terpos E. Circulating activin-A is elevated in postmenopausal women with low bone
mass: the three-month effect of zoledronic acid treatment. Osteoporosis International
2013;24:2127-32.
181. Dri AP, Politou M, Gialeraki A, Bagratuni T, Kanellias N, Terpos E. Decreased
incidence of EPCR 4678G/C SNP in multiple myeloma patients with thrombosis.
Thrombosis Research 2013;132:400-1.
182. Bagratuni T, Kastritis E, Politou M, Roussou M, Kostouros E, Gavriatopoulou M,
Eleutherakis-Papaiakovou E, Kanelias N, Terpos E, Dimopoulos MA. Clinical and
genetic factors associated with venous thromboembolism in myeloma patients treated
with lenalidomide-based regimens. American Journal of Hematology 2013;88:765-70.
183. Diamantopoulos PT, Kalotychou V, Polonyfi K, Sofotasiou M, Anastasopoulou A,
Galanopoulos A, Spanakis N, Vassilakopoulos T, Angelopoulou M, Siakantaris M,
Variami E, Poziopoulos C, Terpos E, Kollia P, Viniou NA. Correlation of Fc-γ RIIA
polymorphisms with latent Epstein-Barr virus infection and latent membrane protein 1
expression in patients with low grade B-cell lymphomas. Leukemia & Lymphoma
2013;54:2030-4.
184. Polyzos SA, Kountouras J, Papatheodorou A, Katsiki E, Patsiaoura K, Zafeiriadou E,
Zavos C, Papadopoulou E, Terpos E. Adipocytokines and cytokeratin-18 in patients with
nonalcoholic fatty liver disease - Introduction of CHA index. Annals of Hepatology
2013;12:749-57.
185. Terpos E, Christoulas D, Kastritis E, Katodritou E, Pouli A, Michalis E, Papassotiriou I, Dimopoulos MA. The Chronic Kidney Disease Epidemiology Collaboration
Cystatin-C (CKD-EPI-CysC) equation has an independent prognostic value for overall
survival in newly-diagnosed patients with symptomatic multiple myeloma; is it time to
change from MDRD to CKD-EPI-CysC equations? European Journal of Haematology
2013;91:347-55.
186. Tsakiri EN, Sykiotis GP, Papassideri IS, Terpos E, Dimopoulos MA, Gorgoulis VG,
Bohmann D, Trougakos IP. Proteasome dysfunction in Drosophila signals to an Nrf2dependent regulatory circuit aiming to restore proteostasis and prevent premature agin.
Aging Cell 2013;12:802-13.
187. Polyzos SA, Kountouras J, Slavakis A, Zafeiriadou E, Patsiaoura K, Katsiki E, Zavos
C, Papatheodorou A, Terpos E. A novel noninvasive index for nonalcoholic
steatohepatitis: a pilot study. Biomarkers 2013;18:607-13.
188. Gkotzamanidou M, Christoulas D, Souliotis VL, Papatheodorou A, Dimopoulos MA,
Terpos E. Angiogenic cytokines profile in smoldering multiple myeloma: no difference
compared to MGUS but altered compared to symptomatic myeloma. Medical Science
Monitor 2013;19:1188-94.
189. Karadimou A, Gavalas N, Tsiatas M, Sereti E, Trachana P-S, Spyropoulou-Vlachou
M, Karga E, Terpos E, Tsitsilonis O, Dimopoulos MA, Bamias A. Pre-treatment status
and changes in autoantibodies, lymphocytic populations, cytokines and VEGF during
34
sunitinib treatment of metastatic renal cell carcinoma (mRCC). Translational Medicine
2013;5:100124.
190. Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P,
Kartasis Z, Parcharidou A, Michael M, Michalis E, Gika D, Symeonidis A, Pouli A,
Konstantopoulos K, Terpos E, Kastritis E. Significant improvement in the survival of
patients with multiple myeloma presenting with severe renal impairment after the
introduction of novel agents. Annals of Oncology 2014;25:195-200.
191. Katodritou E, Vadikolia C, Lalagianni C, Kotsopoulou M, Papageorgiou G, Kyrtsonis
M-C, Matsouka P, Giannakoulas N, Kyriakou D, Karras G, Anagnostopoulos N, Michali
E, Briasoulis E, Hatzimichael E, Spanoudakis E, Zikos P, Tsakiridou A, Tsionos K,
Anargyrou K, Symeonidis A, Maniatis A, Terpos E. “Real World” data on the efficacy
and safety of lenalidomide and dexamethasone in patients with relapsed/refractory
multiple myeloma who were treated according to the standard clinical practice; a study
of the Greek Myeloma Study Group. Annals of Hematology 2014;93:129-39.
192. Asimakopoulos JV, Terpos E, Papageorgiou L, Kampouropoulou O, Christoulas D,
Giakoumis A, Samarkos M, Vaiopoulos G, Konstantopoulos K, Angelopoulou MK,
Vassilakopoulos TP, Meletis J. The presence of CD55- and/or CD59-deficient
erythrocytic populations in patients with rheumatic diseases reflects an immunemediated bone-marrow derived phenomenon. Medical Science Monitor 2014;20:123-39.
193. Terpos E, Christoulas D, Kastritis E, Katodritou E, Papatheodorou A, Pouli A,
Kyrtsonis M-C, Michalis E, Papanikolaou X, Gkotzamanidou M, Koulieris E,
Gavriatopoulou M, Zervas K, Dimopoulos MA. The combination of lenalidomide and
dexamethasone reduces bone resorption in responding patients with relapsed/refractory
multiple myeloma but has no effect on bone formation: final results on 205 patients of
the Greek Myeloma Study Group. American Journal of Hematology 2014;89:34-40.
194. Diamantopoulos PT, Polonyfi K, Sofotasiou M, Mantzourani M, Galanopoulos A,
Spanakis N, Papadopoulou V, Kalala F, Iliakis T, Zareifi DS, Kodandreopoulou E,
Vassilakopoulos T, Angelopoulou M, Siakantaris M, Terpos E, Variami E, Kollia P,
Vaiopoulos G, Pangalis G, Viniou NA. Survivin messenger RNA levels in Epstein-Barr
Virus-positive patients with leukemic low-grade B-cell lymphomas expressing the latent
membrane protein 1: evidence of apoptotic function? Clinical Lymphoma, Myeloma &
Leukemia 2014;14:56-60.
195. Katodritou E, Terpos E, Kelaidi C, Kotsopoulou M, Delimpasi S, Kyrtsonis MC,
Symeonidis A, Giannakoulas N, Stefanoudaki A, Christoulas D, Chatziaggelidou C,
Gastari V, Spyridis N, Verrou E, Konstantinidou P, Zervas K, Dimopoulos MA. Treatment
with bortezomib-based regimens improves overall response and predicts for survival in
patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma
study group Treatment with bortezomib-based regimens improves overall response and
predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis
of the Greek myeloma study group. American Journal of Hematology 2014;89:145-50.
196. Anastasilakis AD, Polyzos SA, Makras P, Savvides M, Sakellariou GT, Gkiomisi A,
Papatheodorou A, Terpos E. Circulating periostin levels do not differ between
postmenopausal women with normal and low bone mass and are not affected by
zoledronic acid treatment. Hormone & Metabolic Research 2014;46:145-9.
197. Kastritis E, Terpos E, Dimopoulos MA. Think to prevent before than to treat renal
impairment in multiple myeloma: do not forget tubular damage mimicking Fanconi
syndrome-Reply. Expert Opinion on Pharmacotherapy 2014;15:300.
35
198. Voskaridou E, Komninaka V, Karavas A, Terpos E, Akianidis V, Christoulas D.
Combination therapy of deferasirox and deferoxamine shows significant improvements
in markers of iron overload in a patient with β-thalassaemia major and severe iron
burden. Transfusion 2014;54:646-9.
199. Zagouri F, Kastritis E, Symeonidis AS, Giannakoulas N, Katodritou E, Delimpasi S,
Repousis P, Terpos E, Dimopoulos MA. Immunoglobulin D myeloma: clinical features
and outcome in the era of novel agents. European Journal of Haematology 2014;92:30812.
200. Terpos E, Christoulas D, Kastritis E, Roussou M, Migkou M, EleutherakisPapaiakovou E, Gavriatopoulou M, Gkotzamanidou M, Kanellias N, Manios E,
Papadimitriou C, Dimopoulos MA. VTD consolidation, without bisphosphonates, reduces
bone resorption and is associated with a very low incidence of skeletal-related events in
myeloma patients post-ASCT. Leukemia 2014;28:928-34.
201. Gkotzamanidou M, Terpos E, Bamia C, Kyrtopoulos SA, Sfikakis PP, Dimopoulos
MA, Souliotis VL. Progressive changes in chromatin structure and DNA damage
response signals in bone marrow and peripheral blood during myelomagenesis.
Leukemia 2014;28:1113-21.
202. Abdulkadyrov KM, Salogub GN, Khuazheva NK, Sherman ML, Laadem A, Barger R,
Knight R, Srinivasan S, Terpos E. Sotatercept in patients with osteolytic lesions of
multiple myeloma. British Journal of Haematology 2014;165:814-23.
203. Liatis S, Sfikakis PP, Tsiakou A, Stathi C, Terpos E, Katsilambros N, Makrilakis K.
Baseline osteocalcin levels and incident diabetes in a 3-year prospective study of highrisk individuals. Diabetes and Metabolism 2014;40:198-203.
204. Melea PI, Melakopoulos I, Kastritis E, Tesseromatis C, Margaritis V, Dimopoulos
MA, Terpos E. Conservative treatment of bisphosphonate-related osteonecrosis of the
jaw in multiple myeloma patients. International Journal of Dentistry 2014;2014:427273.
205. Makarona K, Caputo VS, Costa JR, Liu B, O’Connor D, Iskander D, Roper D,
Robertson L, Bhatnagar N, Terpos E, Georgiou E, Papaioannou M, Layton M, Luzzatto
L, Roberts I, Karadimitris A. Transcriptional and epigenetic basis for restoration of G6PD
enzymatic activity in human G6PD-deficient cells. Blood 2014;124:134-41.
206. Stamatelopoulos K, Athanasouli F, Pappa T, Labrinoudaki I, Papamichael C,
Polymeris A, Georgiopoulos G, Vemmou A, Sarika L, Terpos E, Alevizaki M.
Hemodynamic markers and subclinical atherosclerosis in postmenopausal women with
primary hyperparathyroi-dism. Journal of Clinical Endocrinology and Metabolism
2014;99:2704-11.
207. Katodritou E, Terpos E, Symeonidis AS, Pouli A, Kelaidi C, Kyrtsonis MC,
Kotsopoulou M, Delimpasi S, Christoforidou A, Giannakoulas N, Viniou NA,
Stefanoudaki E, Hadjiaggelidou C, Christoulas D, Verrou E, Gastari V, Papadaki S,
Polychronidou G, Papadopoulou A, Giannopoulou E, Kastritis E, Kouraklis A,
Konstantinidou P, Anagnostopoulos A, Zervas K, Dimopoulos MA. Clinical features,
outcome, and prognostic factors for survival and evolution to multiple myeloma of
solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients.
American Journal of Hematology 2014;89:803-8.
208. Gkotzamanidou M, Terpos E, Kastritis E, Dimopoulos MA. Hematologic response
and stabilization of renal function in a patient with light chain deposition disease after
36
lenalidomide treatment: a novel therapeutic approach? Clinical Lymphoma Myeloma &
Leukemia 2014;14:e179-81.
209. Kastritis E, Zagouri F, Symeonidis A, Roussou M, Sioni A, Pouli A, Delimpasi S,
Katodritou E, Michalis E, Michael M, Hatzimichael E, Vassou A, Repousis P,
Christophoridou A, Kartasis Z, Stefanoudaki E, Megalakaki C, Giannouli S, Kyrtsonis
MC, Konstantopoulos K, Spyroupoulou-Vlachou M, Terpos E, Dimopoulos MA.
Preserved levels of uninvolved immunoglobulins are independently associated with
favorable outcome in patients with symptomatic multiple myeloma. Leukemia
2014;28:2075-9.
210. Kastritis E, Moulopoulos LA, Terpos E, Koutoulidis V, Dimopoulos MA. The
prognostic importance of the presence of more than one focal lesion in spine MRI of
patients with asymptomatic (smoldering) multiple myeloma. Leukemia 2014;28:2402-3.
211. Voskaridou E, Balassopoulou A, Boutou E, Komninaka V, Christoulas D,
Dimopoulou M, Delaki EE, Loukopoulos D, Terpos E. Pregnancy in beta-thalassemia
intermedia: 20-year experience of a Greek thalassemia center. European Journal of
Haematology 2014;93:492-9.
212. Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M,
McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek
R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, Dimopoulos MA,
Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV. Geriatric
assessment predicts survival and toxicities in elderly myeloma: an International Myeloma
Working Group report. Blood 2015;125:2068-7.
213. Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Sakellariou G, Savvidis M,
Papatheodorou A, Kokkoris P, Terpos E. Circulating semaphorin-4D and plexin-B1
levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic
acid, denosumab or teriparatide treatment. Expert Opinion on Therapeutic Targets
2015;19:299-306.
214. Kastritis E, Roussou M, Gavriatopoulou M, Migkou M, Kalapanida D, Pamboucas C,
Kaldara E, Ntalianis A, Psimenou E, Toumanidis S, Tasidou A, Terpos E, Dimopoulos
MA. Long term outcomes of primary systemic light chain (AL) amyloidosis in patients
treated upfront with bortezomib or lenalidomide and the importance of risk adapted
strategies. American Journal of Hematology 2015;90:E60-5.
215. Gertz MA, Terpos E, Dispenzieri A, Kumar S, Shah RA, Orlowski R, Kastritis E,
Dimopoulos MA, Shah J. Therapy-related myelodysplastic syndrome/acute leukemia
after multiple myeloma in the era of novel agents. Leukemia & Lymphoma
2015;56:1723-6.
216. Kastritis E, Gavriatopoulou M, Dimopoulos MA, Eleutherakis-Papaiakovou E,
Kanellias N, Roussou M, Pamboucas C, Toumanidis ST, Terpos E. Osteoprotegerin is a
significant prognostic factor for overall survival in patients with primary systemic
amyloidosis independent of the Mayo staging. Blood Cancer Journal 2015;5:e319.
217. Dimopoulos MA, Petrucci MT, Foa R, Catalano J, Kropff M, Terpos E, Zhang J,
Grote L, Jacques C, Palumbo A. Impact of maintenance therapy on subsequent
treatment in patients with newly diagnosed multiple myeloma: use of "progression-free
survival 2" as a clinical trial end-point. Haematologica 2015;100:e328-e330.
218. Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Roussou M, Hadjiharissi E, Symeonidis
A, Repoussis P, Michalis E, Delimpasi S, Tsatalas K, Tsirigotis P, Vassou A, Vervessou
37
E, Katodritou E, Gika D, Terpos E, Dimopoulos MA. Dexamethasone, rituximab, and
cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final
analysis of a phase 2 study. Blood 2015;126:1392-4.
219. Dimopoulos MA, Terpos E. Reply to D.L. Cooper. Journal of Clinical Oncology
2015;33:2926-7.
220. Liapis K, Kastritis E, Bagratouni T, Vassiliou S, Papachristidis A, Charitaki E,
Alevizopoulos N, Harhalakis N, Terpos E, Delimpasi S, Dimopoulos MA. Early tumor-cell
gene expression changes may predict the response to first-line bortezomib-based
therapy in patients with newly diagnosed multiple myeloma. Journal of BUON
2015;20:1314-21.
221. Komninaka V, Kolomodi D, Christoulas D, Marinakis T, Papatheodorou A, Repa K,
Voskaridou E, Revenas K, Terpos E. Evaluation of bone involvement in patients with
Gaucher disease: a semi-quantitative magnetic resonance imaging method (using ROI
estimation of bone lesion) as an alternative method to semi or quantitative methods
used so far. European Journal of Haematology 2015;95:342-51.
222. Kastritis E, Kyrtsonis MC, Morel P, Gavriatopoulou M, Hatjiharissi E, Symeonidis AS,
Vassou A, Repousis P, Delimpasi S, Sioni A, Michalis E, Michael M, Vervessou E,
Voulgarelis M, Tsatalas C, Terpos E, Dimopoulos MA. Competing risk survival analysis
in patients with symptomatic Waldenstrom’s Macroglobulinemia: the impact of disease
unrelated mortality and of rituximab-based primary therapy. Haematologica
2015;100:e446-9.
223. Katodritou E, Terpos E, Kastritis E, Delimpasis S, Symeonidis AS, Repousis P,
Kyrtsonis MC, Vadikolia C, Michalis E, Polychronidou G, Michael M, Papadaki S,
Papathanasiou M, Kokoviadou K, Kioumi A, Vlachaki E, Hadjiaggelidou C, Kouraklis A,
Patsias I, Gavriatopoulou M, Kotsopoulou M, Verrou E, Gastari V, Christoulas D,
Giannopoulou E, Pouli A, Konstantinidou P, Anagnostopoulos A, Dimopoulos MA. Lack
of survival improvement with novel anti-myeloma agents for patients with multiple
myeloma and central nervous system involvement: the Greek Myeloma Study Group
experience. Annals of Hematology 2015;94:2033-42.
224. Papassotiriou GP, Kastritis E, Gkotzamanidou M, Christoulas D, EleutherakisPapaiakovou E, Migkou M, Gavriatopoulou M, Roussou M, Margeli A, Papassotiriou I,
Dimopoulos MA, Terpos E. Neutrophil Gelatinase-Associated Lipocalin and Cystatin C
are sensitive markers of renal injury in patients with Multiple Myeloma. Clinical
Lymphoma Myeloma & Leukemia 2016;16:29-35.
225. Charitaki E, Kastritis E, Petraki C, Liapis K, Adamidis K, Apostolou T,
Christodoulidou C, Nikolopoulou N, Terpos E, Nakopoulou L, Dimopoulos MA.
Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association
with renal function at the time of kidney biopsy. Clinical Nephrology 2016;85:44-54.
226. Raje N, Vadhan-Raj S, Willenbacher W, Terpos E, Hungria V, Spencer A, Alexeeva
Y, Facon T, Stewart AK, Feng A, Braun A, Balakumaran A, Roodman GD. Evaluating
results from the multiple myeloma patient subset treated with denosumab or zoledronic
acid in a randomized phase 3 trial. Blood Cancer Journal 2016;6:e378.
227. Vassilakopoulos TP, Pangalis GA, Chatziioannou S, Papageorgiou S, Angelopoulou
MK, Galani Z, Kourti G, Prassopoulos V, Leonidopoulou T, Terpos E, Dimopoulou MN,
Sachanas S, Kalpadakis C, Konstantinidou P, Boutsis D, Stefanoudaki E, Kyriazopoulou
L, Siakantaris MP, Kyrtsonis MC, Variami E, Kotsianidis I, Symeonidis A, Michali E,
Katodritou E, Kokkini G, Tsatalas C, Papadaki H, Dimopoulos MA, Sotiropoulos V,
38
Pappa V, Karmiris T, Meletis J, Apostolidis J, Datseris I, Panayiotidis P,
Konstantopoulos K, Roussou P, Rondogianni P. PET/CT in primary mediastinal large Bcell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding
prognostic significance and implications for subsequent radiotherapy. Leukemia
2016;30:238-42.
228. Polyzos SA, Anastasilakis AD, Kountouras J, Makras P, Papatheodorou A, Kokkoris
P, Sakellariou GT, Terpos E. Circulating sclerostin and Dickkopf-1 levels in patients with
nonalcoholic fatty liver disease. Journal of Bone and Mineral Metabolism 2016; in press.
229. Body JJ, Pereira J, Sleeboom H, Maniadakis N, Terpos E, Acklin YP, Finek J,
Gunther O, Hechmati G, Mossman T, Costa L, Rogowski W, Nahi H, von Moos R.
Health resource utilization associated with skeletal-related events: results from a
retrospective European study. European Journal of Health Economics 2016; in press.
230. Cohen YC, Joffe E, Benyamini N, Dimopoulos MA, Terpos E, Trestman S, HeldKuznetsov V, Avivi I, Kastritis E. Primary failure of bortezomib in newly diagnosed
multiple myeloma - understanding the magnitude, predictors, and significance. Leukemia
& Lymphoma 2016; in press.
231. Bagratuni T, Terpos E, Eleutherakis-Papaiakovou E, Kalapanida D, Gavriatopoulou M,
Migkou M, Liacos CI, Tasidou A, Matsouka C, Mparmparousi D, Dimopoulos MA, Kastritis E.
TLR4/TIRAP polymorphisms are associated with progression and survival of patients
with symptomatic myeloma. British Journal of Haematology 2016; in press.
Authorship among 341 publications (328 in journals of Web of Science/ISI):
1st author in 85 (25%), 2nd author in 54 (15.8%) & last author in 80 (23.4%)
Total impact factor (IF) of the above publications: 1667.733 (median IF: 5.084)
Web of Science (ISI)-Citations:
8,945
Scopus-Citations:
9,509
h-index (ISI):
47
h-index (Scopus):
47
39